Abstract

A current global limitation to the timely and equitable patient access to PSMA-based therapies for prostate cancer (PCa) is the insufficient PET capacity for pretreatment imaging. However, the extensive global availability of SPECT cameras renders this imaging technology as an attractive alternative. The lack of regulatory approved PSMA radioligands for SPECT imaging of PCa prompted us to design new 99mTc-labeled radioligands with a fast pharmacokinetic profile by harnessing proven complexation of the [99mTc][TcO]3+ core by a bis(aminoethanethiol) chelator. Six 99mTc-labeled PSMA radioligands were synthesized and biologically characterized in cell-based assays and by SPECT imaging in LNCaP tumor-bearing mice. From this series, [99mTc]TcO-5 ([99mTc]TcO-ABX474, Kd(PSMA) = 6.1 ± 1.7 nM) displayed the most advantageous properties for SPECT imaging of PCa: high and fast tumor uptake accompanied by rapid clearance from nontarget tissues, leading to faster pharmacokinetics than observed for the reference [99mTc]Tc-PSMA-I&S. Furthermore, [99mTc]TcO-5 performed similar to the established PSMA–PET radioligand [68Ga]Ga-PSMA-11.
1. Introduction
Prostate cancer (PCa) is the second most commonly occurring cancer in men and the fourth most common cancer overall, with around 1.4 million new cases in 2020.1 It is also the fifth most common cause of cancer-related deaths worldwide and has the highest mortality rates among populations in less-developed regions, in particular in the Caribbean and in Middle and Southern Africa.2
The prostate-specific membrane antigen (PSMA), discovered in 19873 and also known as glutamate carboxypeptidase II, N-acetyl-l-aspartyl-l-glutamate peptidase I or folate hydrolase I, is a type II transmembrane protein, which consists of 750 amino acids and is present in healthy prostate tissue, kidneys, salivary glands, the intestinal tract and with some minimal expression in the brain.4,5 The 100 to 1000-fold higher expression of PSMA in PCa cells compared to healthy tissues has made it an increasingly attractive target for diagnosis and therapy of PCa and metastasis thereof.6 In particular, the development and utilization of PSMA-binding radioligands have become of significant importance in PCa management.7 This is reflected in the recent regulatory approvals of numerous 68Ga- and 18F-labeled PET tracers as prostate cancer diaganostics8 and 177Lu-PSMA-617 for radioligand therapy.9 All of these compounds are based on an urea-containing pharmacophore, which enables binding to PSMA,7,10,11 but differ structurally in their linker and the radionuclide-containing group.
Despite early efforts12−14 and a recent surge in development and clinical translation of 99mTc-labeled PSMA radioligands,15−19 which were reviewed recently in detail by Brunello et al.,20 no such radioligand has yet received regulatory approval for SPECT imaging of PCa. One may assume that this is probably due to the lower sensitivity21 and generally lower resolution of SPECT in comparison to PET.20 Only 99mTc-MIP-1404 advanced to a phase 3 study to evaluate its safety and efficacy in SPECT/CT imaging for the detection of clinically significant PCa. It was reported at a conference that this study did not meet the prespecified sensitivity end point.22 In the absence of a more detailed report it can only be speculated that the results of this study did not justify rapid further development of 99mTc-MIP-1404. However, the recent advancement in the design of SPECT scanners has led to enhancements in photon sensitivity and spatial resolution, thereby reducing the differences between PET and SPECT to a considerable extent and making quantification possible.20,23 Simple kit-based radiosynthesis with [99mTc]TcO4– eluate from commercially available 99 Mo/99mTc generators, along with the widespread availability of SPECT cameras, renders this imaging technology accessible to patients even in regions with limited resources. Similar to PET, potential applications in SPECT imaging of PCa include initial diagnosis, primary staging and (re)staging, detection of biochemical recurrence as well as determination of eligibility for and monitoring of PSMA-based therapies, especially radioligand therapy.6−8,20 In most of these indications, but particularly in case of the latter, rapid and local access for the patients as well as cost-effectiveness can outweigh ultimate resolution and sensitivity, thus accelerating the process from patient referral until treatment initiation and saving PET capacities in specialized centers for exceptional cases.24−26
Similar to a PSMA radioligand for PET imaging of PCa, a PSMA ligand for 99mTc-SPECT imaging of PCa comprises a PSMA-binding pharmacophore group conjugated via a linker to a suitable chelator for radionuclide complexation. The pharmacophore typically consists of a Glu-urea-Glu- or a Glu-urea-Lys-motif, which tightly interacts with the S1’ glutamate pocket, the dinuclear ZnII active site and the S1-pocket of the PSMA protein.10−12,27,28 The linker moiety not only connects the pharmacophore and the chelator. It rather influences binding affinity and pharmacological properties, which can thus be optimized by careful adjustment of linker-length, -rigidity, -polarity and -charge.10,29 The complex formed by the chelator and the radionuclide has to be of high thermodynamic and kinetic stability to prevent the undesired release of 99mTc. The γ radiation emitted (mainly at 140.5 keV) during the decay of 99mTc (half-life: 6.006 h) to 99Tc is detected via planar scintigraphy or SPECT.
Strategies to achieve stable complexes with the transition metal radionuclide 99mTc include: (1) tetradentate chelation of the [99mTc]TcV-oxo core by NxS4-x chelators, (2) [99mTc]TcV-hydrazido complexes using HYNIC (6-hydrazinonicotinamide) and a suitable coligand (e.g., N,N-diacetic acid or tricine), (3) mono-, bi- or tridentate [99mTc]TcI-tricarbonyl complexes with various nitrogen-containing chelators, and (4) complexes of a [99mTc]TcVN core with sulfur-containing chelators and diphosphine coligands.20,23 The structural features of the selected chelator system affect both the stability of the complex and the physicochemical properties of the entire molecule, thereby contributing to its pharmacokinetic properties.30 For example, within the class of tetradentate NxS4-x-type chelators for complexation of [99mTc][TcVO]3+,31,32 the '3 + 1’ complexes, combining a tridentate (S3 or NS2) and a monodentate (S) thiol ligand, were found to be of limited applicability due to an observed ligand exchange in vivo.33,34 Already before the development of structurally modified N3S chelators, as exemplified by the mas3-chelator in [99mTc]Tc-PSMA-I&S,15 such drawbacks have been overcome by use of the class of N2S2–type chelators based on bis(aminoethanethiol) (BAT or DADT) or monoamino-monoamide dithiol (MAMA). Within this class, two BAT-based [99mTc][TcVO]3+-containing radioligands, [99mTc]TcO-l,l-ECD35 and [99mTc]TcO-TRODAT-136 (Figure 1A), have been developed and translated to the clinic.
Figure 1.
(A) Clinically relevant radiotracers based on [99mTc]TcVO–N2S2 complexes. (B) General structure of a N-functionalized BAT-chelator with bis(gem-dimethyl) substitution.
We envisioned novel PSMA ligands for SPECT imaging based on the Glu-urea-Lys-Sub-Lys motif12,15,37 and BAT-chelators, which are known to form stable, neutral and lipophilic complexes with [TcVO]3+ and [ReVO]3+.35,36,38,39 In particular, the bis(gem-dimethyl)-substituted BAT motif (see Figure 1B), known from a few examples from the literature,31,38,39 came into our focus. Studies have shown that an increasing number of methyl groups in the corresponding 99mTc complexes resulted in higher stability in rat plasma and increased brain uptake in rats. The latter is consistent with higher lipophilicity, i.e. higher octanol–water partition coefficients (log D).31,39 To the best of our knowledge, no radioligand with a bis(gem-dimethyl)-substituted BAT-chelator has yet been investigated in clinical trials or been developed for PSMA-based theranostics. Furthermore, we introduced two additional amino acids in the N-terminal part of the linker of the PSMA ligands to allow for structural variation to optimize their binding affinity for PSMA, their internalization into PSMA-expressing tumor cells and their in vivo biodistribution (Figure 2). Pursuing this approach we intended to overcome limitations of 99mTc-labeled PSMA radioligands, which were available when the project was initiated, like slow pharmacokinetics requiring late imaging (at least 2 h p.i) for optimal tumor contrast in humans, discontinuation of the Isolink kit required for the synthesis of [99mTc]TcI-tricarbonyl complexes and the sensitivity toward reaction conditions and coligands used for labeling of HYNIC-derivatives with 99mTc.20,23,40 Similar considerations also prompted others to develop novel 99mTc-labeled PSMA radioligands.16,17
Figure 2.
Structures of the synthesized PSMA ligands.
2. Results
The first series of compounds comprised the parent compound 1 and the two derivatives 2 and 3 with two d-phenylalanine moieties each and varying stereochemical orientation at the alpha-carbon of the lysine moiety in the linker. In the second set we focused on d-lysine in the linker and introduced the amino acids 3-iodo-d-tyrosine (4) and glutamic acid (5 and 6), which bear polar hydroxyl or carboxyl groups in the side chain. Compounds 1-5 had the tetramethylated BAT-chelator R1, whereas 6 was functionalized with the residue R2, which includes a desmethyl-BAT-chelator and a succinic acid unit as inverter to allow for coupling to the N-terminus of the PSMA ligands.
2.1. Synthesis of PSMA Ligands
The compounds were synthesized via solid phase peptide synthesis based on tBu-protected carboxylic acids as well as Fmoc and Dde as orthogonal amino protecting groups. The synthesis strategy for compounds 1-5 is shown in Scheme 1. The two PMB-protected bifunctional BAT-chelator building blocks 7 and 9 were synthesized following literature procedures41−44 (see Schemes S1 and S2). For 6 the synthesis strategy was inverted in order to allow coupling of the chelator in the last step before resin cleavage and deprotection (Scheme 2). This was necessary to avoid unwanted side reactions of the unprotected secondary amine in the backbone of the chelator building block 9. Cleavage from the resin and final deprotection of acid labile tBu protecting groups was achieved by treatment with TFA/TIS/H2O. The PMB groups were removed using Hg(OAc)2, anisole and TFA followed by precipitation of HgS with H2S to get the deprotected thiol-groups.36 Alternatively, to avoid the use of toxic mercury(II) salts, a mixture of TFA/TIS/EDT/water with subsequent addition of TFMSA was used to cleave the peptide from the resin and to remove tBu and PMB groups in a one-pot procedure. Final purification by RP-HPLC furnished the PSMA ligands 1-6.
Scheme 1. Synthesis of 1-5.
(i) 20% piperidine in DMF; (ii) corresponding Fmoc-protected amino acid, HATU, HOAt, DIPEA, DMF; (iii) chelator building block 7, PyBOP, DIPEA, DMF; (iv) 2% N2H4·H2O in DMF; (v) suberic acid N-hydroxysuccinimide ester, DIPEA, DMF; (vi) TSTU, DIPEA, DMF; (vii) Fmoc-l-Lys-OtBu, DIPEA, DMF; (viii) di-tert-butyl (1H-imidazole-1-carbonyl)-l-glutamate 8, NMM, DMF; (ix) TFA/TIS/H2O/EDT (92.5:2.5:2.5:2.5, v/v/v/v); (x) 10% TFMSA; (xi) TFA/TIS/H2O (95:2.5:2.5, v/v/v); (xii) TFA, anisole, Hg(OAc)2; (xiii) H2S.
Scheme 2. Synthesis of 6.
(i) 20% Piperidine in DMF; (ii) suberic acid N-hydroxysuccinimide ester, DIPEA, DMF; (iii) TSTU, DIPEA, DMF; (iv) Fmoc-l-Lys-OtBu, DIPEA, DMF; (v) di-tert-butyl (1H-imidazole-1-carbonyl)-l-glutamate 8, NMM, DMF; (vi) 2% N2H4·H2O in DMF; (vii) Fmoc-l-Glu(OtBu)–OH, PyBOP, HOBt, DIPEA, DMF; (viii) Succinic anhydride, DIPEA, DMF; (ix) chelator building block 9, DIPEA, DMF; (x) TFA/TIS/H2O/EDT (92.5:2.5:2.5:2.5, v/v/v/v); (xi) 10% TFMSA.
2.2. Radiolabeling with Technetium-99m
The radiosyntheses were performed, after previous optimization, under weakly acidic conditions (pH 5–6.5) by means of stannous chloride as reducing agent, d-mannitol as bulking agent, and calcium α-d-glucoheptonate to enable an intermediate complexation of 99mTc in oxidation state +5 as depicted in Scheme 3.45,46 Furthermore, the reaction mixture contained 50 μg of the respective PSMA ligand (1-6) and up to 7 GBq [99mTc]NaTcO4 (see Table S1). After final addition of stannous chloride in HCl the mixture was kept at r.t. for 20 min and at 80 °C for another 20 min. Figure 3A summarizes the course of the 99mTc-labeling reaction as well as the obtained radiochemical purities (RCP) for each product. In short, the major part of product formation occurred during 20 min at r.t., but for some of the ligands higher temperatures were required to achieve near complete conversions. Byproduct formation or unreacted [99mTc]TcO4– remained at a tolerable level, as shown by HPLC and TLC analyses (Figures S1, S6, and Table S1), considering that a RCP of >90% is a typical criterion applied for batch release of clinically used 99mTc-labeled radiopharmaceuticals.46 Finally, without the necessity for further purification, the radioligands were obtained with average RCP (determined by radio-HPLC, method A) of 89.8% (for [99mTc]TcO-4) to 97.4% (for [99mTc]TcO-5).
Scheme 3. (A) Synthesis of the Radioligands [99mTc]TcO-1 to -6 by a Two-Step Procedure: Reduction and Formation of the Intermediate Complex, and Subsequent Ligand Exchange with the Respective Precursor to Form the Desired Complex and (B) Exemplary Structure of the 99mTc-Labeled PSMA Radioligand [99mTc]TcO-5.
Figure 3.
Radiosynthesis and in vitro stability of [99mTc]TcO-1 to -6. (A) Radiochemical yields (RCYs) after different steps of the labeling procedure as indicated in the legend, radiochemical purity (RCP, for n, see Table S1) = RCY80 °C at 20 min. In vitro stability (B) in native plasma from male CD-1 mice (37 °C, n = 2–3, also see Figure S3) and human (37 °C, n = 4–5, also see Figure S3), (C) in saline (25 °C, n = 2, also see Figure S4), and (D) in PBS (25 °C, n = 2, also see Figure S5). RCY and amounts of intact radioligand (%) determined by radio-HPLC (method A, for [99mTc]TcO-6: method B) and normalized to the percentage of radioligand determined immediately after preparation (except for A). For [99mTc]TcO-6 in (C) and (D): 6 h instead of 4 h.
During the complexation of [99mTc][TcVO]3+ with 1-6 a chiral center was created within the chelate complex by quaternization of the functionalized nitrogen atom. Accordingly, due to the pharmacophore’s chirality, the chirality of the quaternary nitrogen atom (R and S), and the orientation of the oxo-technetium-99m group with respect to the functionalization of the nitrogen atom (syn and anti), four diastereomers can be formed (see Figure S11).47 By using radio-HPLC analysis with isocratic elution, two peaks of equal peak area were separated for all of the synthesized radioligands, with the exception of [99mTc]TcO-2 (see Figure S2 and Table S1), which likely result from two diastereomers (quaternary nitrogen in R- and S-configuration), present in syn or anti configuration. Furthermore, the analyses showed additional peaks with low intensity that potentially correspond to pairs of diastereomers (quaternary nitrogen in R- and S-configuration), both with the same less preferred orientation of the oxo-technetium-99m relative to the functionalization of the nitrogen atom.
2.3. In Vitro Stability of the Radioligands
2.3.1. Stability in Saline and PBS
Incubation of the radioligands [99mTc]TcO-1 to -6 in saline (0.9% NaCl) or phosphate-buffered saline (PBS) at 25 °C for up to 20 h revealed considerable differences in their stability, which was determined by radio-HPLC (Figure 3C,D). For [99mTc]TcO-2, -3 and -4, the stability in saline was much lower than in PBS, with [99mTc]TcO-4 as the most striking example showing an intact fraction of 98% in PBS but only 17% in saline after 20 h. For [99mTc]TcO-1, -5 and -6, stability was comparable for both media. However, the highest stability in both saline and PBS was shown for [99mTc]TcO-5 and -6, as in saline 93.2 and 92.6% and in PBS > 99 and 97.6% of the initial fraction of the radioligand was present after 4 h.
2.3.2. In Vitro Stability in Plasma
For selected radioligands ([99mTc]TcO-1, -2, -3, and -5), stability was tested in native mouse and human plasma at 37 °C. The samples were prepared by protein precipitation with MeOH/water (4:1, v/v) at defined time points and analyzed by radio-HPLC. As depicted in Figures 3B and S3, all radioligands investigated were highly stable in mouse plasma as the proportion of unchanged radioligand was still ≥98% after 6 h. [99mTc]TcO-5 showed similar stability in human plasma as 96% of unchanged radioligand remained present after the same period of time. For the radioligands investigated the efficiency of extraction of total activity from mouse and human plasma was sufficiently high (91.5–95.1%) as shown in Table S2.
2.4. Cell-Based Assays
The radioligands were characterized in cell-based assays using the human prostate adenocarcinoma cell line LNCaP, which highly expresses PSMA,48−50 to determine binding affinity and receptor-mediated internalization. All investigated 99mTc-labeled PSMA radioligands displayed high affinity, i.e. Kd values in the low nanomolar range, for PSMA-expressing LNCaP prostate cancer cells and were compared with the reference compound [68Ga]Ga-PSMA-11 (Table 1). Of the 99mTc-labeled radioligands [99mTc]TcO-4, [99mTc]TcO-5 and [99mTc]TcO-6 showed slightly higher affinities than [99mTc]TcO-1, [99mTc]TcO-2, [99mTc]TcO-3 and the reference compound [68Ga]Ga-PSMA-11. The binding capacities of [99mTc]TcO-2 and [99mTc]TcO-3 were slightly lower than those of the other radioligands (Table 1). However, these data should be treated with caution, since [99mTc]TcO-2 and [99mTc]TcO-3 showed a considerable amount of nonspecific binding not only to the cells but also to the plastic of the well plates, both without and in the presence of the high-affinity PSMA-ligand 2-(phosphonomethyl)pentanedioic acid (2-PMPA). [99mTc]TcO-4 also revealed a substantial part of nonspecific binding (see Figure S7). In contrast, only a low level of nonspecific binding was observed for the 99mTc-labeled compounds [99mTc]TcO-1, [99mTc]TcO-5 and [99mTc]TcO-6 (see Figure S7). The compounds [99mTc]TcO-2 and [99mTc]TcO-3 were excluded from internalization experiments due to their nonspecific binding, particularly their adherence to the plastic material of the well plates. In contrast to the pronounced binding of all radioligands to LNCaP cells, there was no evaluable specific binding to PSMA-negative PC3 cells (see Figure S8) confirming the PSMA specificity of the 99mTc-labeled radioligands.
Table 1. Results of Binding and Internalization Assays Using the LNCaP Prostate Cancer Cell Linea.
| internalization
(%ADb/mg
protein) |
surface binding (%ADb/mg
protein) |
|||||
|---|---|---|---|---|---|---|
| radioligand | Kd (nM) | Bmax (pmol/mg) | 4 °C | 37 °C | 4 °C | 37 °C |
| [99mTc]TcO-1 | 14.4 ± 8.2 | 9.0 ± 1.5 | 0.48 ± 0.01 | 1.75 ± 1.08 | 1.95 ± 0.93 | 3.00 ± 1.38 |
| [99mTc]TcO-2 | 15.5 ± 3.1 | 4.7 ± 0.2 | n.d. | n.d. | n.d. | n.d. |
| [99mTc]TcO-3 | 13.3 ± 5.5 | 4.0 ± 0.4 | n.d. | n.d. | n.d. | n.d. |
| [99mTc]TcO-4 | 8.4 ± 0.2 | 10.4 ± 6.2 | 0.37 ± 0.20 | 2.17 ± 0.06 | 1.67 ± 0.24 | 3.29 ± 0.72 |
| [99mTc]TcO-5 | 6.1 ± 1.7 | 10.0 ± 2.7 | 0.52 ± 0.32 | 2.46 ± 0.79 | 2.21 ± 0.35 | 3.70 ± 1.11 |
| [99mTc]TcO-6c | 6.8 ± 0.5 | 12.0 ± 0.3 | 0.20 ± 0.04 | 2.89 ± 0.21 | 2.50 ± 0.38 | 4.54 ± 0.15 |
| [68Ga]Ga-PSMA-11 | 11.6 ± 3.0 | 19.8 ± 2.4 | 0.03 ± 0.02 | 0.52 ± 0.18 | 0.34 ± 0.21 | 0.76 ± 0.20 |
Data shown are mean values (±SEM) of 2, 3, or 4 separate experiments (see Section 5). n.d. denotes not determined.
%AD = percent administered dose.
Saturation assay was performed once with triplicate for the total binding and duplicates for nonspecific binding. Internalization assay was performed once with sextuplicates for the total part and triplicates for the nonspecific part. Data for [99mTc]TcO-6 are mean values (±SD).
The results of the internalization assays show that the investigated 99mTc-labeled PSMA radioligands are internalized to a greater extent than the reference compound [68Ga]Ga-PSMA-11, with [99mTc]TcO-5 and [99mTc]TcO-6 displaying the highest values (Table 1, Figure S9). Temperature-dependent binding and internalization was observed. At an assay temperature of 4 °C, all radioligands were only slightly taken up by the LNCaP cells, while the internalization at 37 °C was at least 3.6-fold higher. The cell surface binding was slightly higher at 37 °C than at 4 °C. Due to the lack of specific binding to PSMA-negative PC3 cells observed for the 99mTc-labeled PSMA radioligands no internalization assays were performed with this cell line.
2.5. Distribution and Tissue-Specific Uptake in Prostate Cancer Xenograft Mice
Upon injection in LNCaP tumor-bearing mice, distribution of the 99mTc-labeled PSMA radioligands, and the clinical references [99mTc]Tc-PSMA-I&S and [68Ga]Ga-PSMA-11 was characterized in vivo at 1 and 4 h after injection, using quantitative SPECT and PET imaging. In addition, the distribution of 99mTc-labeled PSMA radioligands was compared to [99mTc]TcO4– to determine the influence of its residual amount in the radioligand preparations on the biodistribution observed.
2.5.1. Imaging-Derived Biodistribution
All investigated 99mTc-labeled PSMA radioligands enabled visualization of the subcutaneous LNCaP tumors in vivo and were excreted with different preferences for the renal or hepatobiliary pathway (Figure 4A). For most preparations of the 99mTc-labeled PSMA radioligands, in vivo distribution was accompanied by nonspecific uptake in [99mTc]TcO4– target organs such as submandibular/sublingual glands, thyroid gland, and stomach wall. Tissue specificity and intensity of this uptake pattern were similar to those observed after injection of [99mTc]TcO4– reference solutions (vehicle without radioligand containing 1% or 3% of free [99mTc]TcO4–, relative to the initial activity dose of radioligand, Figure 4B). This is in agreement with the radiochemical purities of the radioligand preparations (see Table S1). Furthermore, a blockade of sodium/iodine symporters with sodium perchlorate administered prior to radioligand injection almost completely prevented the uptake of residual [99mTc]TcO4– (as shown for [99mTc]TcO-5 in Figure 4B).
Figure 4.
SPECT imaging with 99mTc-labeled PSMA radioligands detects LNCaP tumor xenografts in mice; maximum intensity projections at indicated time points in comparison with the clinical references [99mTc]Tc-PSMA-I&S (SPECT) and [68Ga]Ga-PSMA-11 (PET). (A) Distribution and tissue-specific uptake. (B) Nonspecific uptake resulting from free residual [99mTc]TcO4– in a [99mTc]TcO-5 preparation was blocked by pretreatment with sodium perchlorate; comparison with [99mTc]TcO4– reference solutions (vehicle containing indicated amounts relative to the initial activity dose of radioligand); white circles indicate the position of subcutaneous tumors; (g) gall bladder, (i) intestine, (k) kidneys, (l) liver, (o) stomach wall, (p) parotid glands, (s) submandibular/sublingual glands, (t) thyroid gland, (u) urinary bladder; (SUV) standardized uptake value; (orange box) best-performing radioligand [99mTc]TcO-5; (green box) reference radioligand [99mTc]Tc-PSMA-I&S; data presented as maximum intensity projections corrected for attenuation, scatter, and decay.
2.5.2. Quantitative Analyses of SPECT and PET Images
Quantitative analyses of SPECT and PET images allowed for comparing the diagnostic performance of PSMA radioligands in vivo based on concentrations and amounts in specific tissues (Figure 5A–H). The novel 99mTc-labeled PSMA radioligands showed a trend toward lower retention in blood compared to [99mTc]Tc-PSMA-I&S (Figure 5A). The lowest blood retention was measured for [99mTc]TcO-1. A trend toward increasing blood retention was observed within the series of [99mTc]TcO-1, -2, -3, and -4. At 1 h after injection, [99mTc]TcO-2, -5, and -6 exhibited similar blood retention in the range of [68Ga]Ga-PSMA-11.
Figure 5.
Distribution and tissue-specific uptake of 99mTc-labeled PSMA radioligands in LNCaP tumor-bearing mice; results from quantitative image analysis at indicated time points in comparison with the clinical references [99mTc]Tc-PSMA-I&S (SPECT) and [68Ga]Ga-PSMA-11 (PET); target specificity was tested by coinjection of radioligands and 2-PMPA. (A) Concentrations in heart contents (blood). (B,C) Proportions of the radioligands undergoing renal (RNL: kidneys + urine) and hepatobiliary (HPBL: gall bladder + liver + intestine) excretion; (D–G) concentrations in indicated tissues; (H) uptake in [99mTc]TcO4– target organs (submandibular/sublingual glands + thyroid gland + stomach wall) resulting from free [99mTc]TcO4– in radioligand preparations compared to reference solutions (vehicle containing indicated amounts of [99mTc]TcO4– relative to the initial activity dose of radioligands); pretreatment with sodium perchlorate blocks the uptake of free [99mTc]TcO4– remaining in a [99mTc]TcO-5 preparation; (I–L) tumor-to-organ ratios; (HPBL) hepatobiliary; (RNL) renal; (SUV) standardized uptake value; data presented as means ± standard deviation; significance of differences was tested for the best-performing radioligand [99mTc]TcO-5 (orange box) compared to [99mTc]Tc-PSMA-I&S (green box) using Fisher’s LSD test: * P < 0.05, † P < 0.01, # P < 0.001.
Excretion of the novel 99mTc-labeled PSMA radioligands was faster compared to [99mTc]Tc-PSMA-I&S. Similar to the clinical references [99mTc]Tc-PSMA-I&S and [68Ga]Ga-PSMA-11, [99mTc]TcO-5 and [99mTc]TcO-6 were predominantly excreted via the renal pathway, whereas [99mTc]TcO-1, -2, -3, and -4 exhibited a strong preference for the hepatobiliary excretion route (Figure 5B,C).
In the kidneys, all novel 99mTc-labeled PSMA radioligands showed lower uptake and retention in the renal cortex compared to [99mTc]Tc-PSMA-I&S (Figure 5D). Lowest uptake was measured for [99mTc]TcO-1, -2, -3, and -4, followed by [99mTc]TcO-5, and [99mTc]TcO-6, both of which exhibited renal uptake similar to [68Ga]Ga-PSMA-11. In addition, the uptake in kidneys decreased when the PSMA-specific competitor 2-PMPA was administered simultaneously with the radioligands. In detail, the blockade was more effective against [99mTc]TcO-1 to -6 (43–86%) when compared to [99mTc]Tc-PSMA-I&S (10–31%).
All PSMA radioligands exhibited low uptake in the liver (Figure 5E). Although tissue concentrations remained low, a trend toward increasing liver uptake was observed within the series of [99mTc]TcO-1, -2, -3, and -4. Liver uptake of [99mTc]TcO-5 was slightly lower compared to [99mTc]TcO-6 and [99mTc]Tc-PSMA-I&S. The lowest liver uptake was measured for [68Ga]Ga-PSMA-11.
All PSMA radioligands showed uptake in tumors that was effectively blocked through simultaneous administration of the competitor 2-PMPA (Figures 5F and S10). Highest concentrations in tumors were observed for [99mTc]TcO-5 and [99mTc]Tc-PSMA-I&S, followed by [99mTc]TcO-6 and [68Ga]Ga-PSMA-11. Compared to the latter, tumor uptake was substantially lower within the series of [99mTc]TcO-1, -2, -3, and -4. Uptake of the PSMA radioligands in parotid glands corresponded to the observed trends in tumor uptake, although concentrations in parotid glands were considerably lower (Figure 5G).
Between 0.9 and 2.4% of the initially administered dose of 99mTc-labeled PSMA radioligand preparations were taken up by submandibular/sublingual glands, thyroid gland, and stomach wall (Figure 5H). These organs typically exhibit high avidity for free [99mTc]TcO4–. Compared to uptake in these organs detected after injection of radioligand-free reference preparations containing defined amounts of [99mTc]TcO4–, the estimated contents of free [99mTc]TcO4– in PSMA radioligand preparations corresponded to 0.5 and 2% (relative to the initial radioligand dose). Accordingly, blockade of sodium iodine symporters with sodium perchlorate prior to the injection of [99mTc]TcO-5 reduced the uptake of free [99mTc]TcO4– to negligible amounts <0.3% relative to the initial dose (Figure 5H).
Among the novel 99mTc-labeled PSMA radioligands [99mTc]TcO-1 to -6, [99mTc]TcO-5 provided the highest tumor contrast relative to blood, kidneys, liver, and muscle. Furthermore, for [99mTc]TcO-5 adequate tumor contrast established in a shorter period of time compared to [99mTc]Tc-PSMA-I&S (Figure 5I–L).
2.5.3. Pharmacokinetics of [99mTc]TcO-5 in LNCaP Tumor-Bearing Mice
The pharmacologic properties of [99mTc]TcO-5 provided favorable imaging performance compared to [99mTc]Tc-PSMA-I&S in LNCaP tumor-bearing mice. Specifically, the pharmacokinetic advantages of [99mTc]TcO-5 over [99mTc]Tc-PSMA-I&S were lower retention in blood, lower uptake and retention in the liver (<8 h after injection), lower uptake and retention in kidneys and muscle (<20 h after injection), and higher uptake in tumors (<1.5 h after injection) (Figure 6A–E). Accordingly, [99mTc]TcO-5 provided higher tumor-to-organ ratios at earlier time points compared to [99mTc]Tc-PSMA-I&S including higher tumor contrasts relative to blood (<4 h after injection), liver (<2.3 h after injection), kidneys (<20 h after injection), and muscle (<10 h after injection) (Figure 6F–I).
Figure 6.
Improved pharmacokinetics of [99mTc]TcO-5 enable faster tumor contrast compared to [99mTc]Tc-PSMA-I&S in LNCaP tumor-bearing mice; time–activity curves from quantitative analysis of SPECT images; animals received an initial dose of 30 MBq; target specificity was tested by blocking specific binding sites with 2-PMPA. (A–E) Tissue-specific time courses of activity concentrations; (F–I) time courses of tumor-to-organ ratios; shaded areas indicate the time frame, where [99mTc]TcO-5 is superior to [99mTc]Tc-PSMA-I&S; (SUV) standardized uptake value; data presented as means ± standard deviation.
2.6. Autoradiographic Studies for [99mTc]TcO-5
We performed in vitro autoradiography on tumor, kidney cortex, and glandula submandibularis tissues of the same LNCaP tumor-bearing mouse model to compare PSMA-specific binding of [99mTc]TcO-5 to tumors and PSMA-expressing off-target tissues such as renal cortex and salivary glands (Figure 7). In these tissue cryosections the total binding (TB) was 2.4- and 42-times higher in tumor compared to kidney cortex and salivary glands (glandula submandibularis) (Figure 7A). Likewise, the PSMA-specific binding could be validated in a competition assay using unlabeled 5 and 2-PMPA as competitors (Figure 7). These in vitro results confirm the high and PSMA-specific binding of [99mTc]TcO-5 found in cell uptake studies with PSMA-expressing LNCaP tumor cells and in LNCaP tumor-bearing mice in vivo.
Figure 7.
[99mTc]TcO-5 in vitro binding study to tumor, kidney cortex, and glandula submandibularis of LNCaP tumor-bearing mice. (A) Exemplary autoradiograms of 10 μm tissue cryosections incubated with [99mTc]TcO-5 or [99mTc]TcO-5 supplemented with 10 μM blocking compounds (unlabeled 5 or 2-PMPA) and (B) corresponding quantification of radioactivity intensity values and tumor-to-tissue signal ratios (n = 3, mean ± SD).
3. Discussion
With the aim of developing a 99mTc-labeled PSMA radioligand for SPECT imaging of PCa capable of complementing PSMA–PET radioligands, we have synthesized and examined six new PSMA radioligands, which are based on the Glu-urea-Lys-Sub-Lys binding motif.12,15,37 In order to optimize the pharmacological properties, the structure of the linker moiety was varied in length and polarity by the incorporation of additional amino acids, also of different stereochemical orientation. Furthermore, two distinct BAT-type chelator units, which enabled the labeling with 99mTc in the form of a [99mTc][TcVO]3+ core, were compared. A straightforward procedure, utilizing [99mTc]NaTcO4, stannous chloride, and calcium α-d-glucoheptonate, furnished the radioligands [99mTc]TcO-1 to -6, without the necessity for purification. It was found that some of the radioligands obtained, exhibited a lack of stability in saline. In contrast, their stability in PBS was sufficiently high, which thus was employed for all subsequent investigations in vitro and in vivo. In vitro stability assessment in native plasma revealed no decomposition of the radioligands examined, thus confirming their suitability for in vivo evaluation.
The parent compound of the series, [99mTc]TcO-1, already displayed a high binding affinity for PSMA in the low nanomolar range in the LNCaP cell-based saturation assay (Kd = 14.4 ± 8.2 nM), which is in the same range as the reference compound [68Ga]Ga-PSMA-11 (Kd = 11.6 ± 3.0 nM). The receptor-mediated internalization was higher for [99mTc]TcO-1 (1.75 ± 1.08%AD/mg Protein) when compared to [68Ga]Ga-PSMA-11 (0.52 ± 0.18%AD/mg Protein).
The introduction of two d-phenylalanine residues in the linker of the radioligands, resulting in [99mTc]TcO-2 and [99mTc]TcO-3, did not affect the PSMA binding affinity (Kd of 15.5 ± 3.1 nM and 13.3 ± 5.5 nM). The stereochemical orientation of the lysine unit in the linker varied between [99mTc]TcO-1 (S), [99mTc]TcO-2 (S) and [99mTc]TcO-3 (R), but all three radioligands displayed similar binding affinities. Due to a potential positive contribution to metabolic stability51 the remaining derivatives were synthesized using d-Lysine (R-configuration) in the linker. When compared to [99mTc]TcO-1 a particularly high proportion of nonspecific binding to the cells and the well plate material (polystyrene) was observed in the cell-based assay for [99mTc]TcO-2 and [99mTc]TcO-3, which was apparently caused by the increased lipophilicity introduced with the two additional phenylalanine moieties. Furthermore, phenylalanine has been described to interact with polystyrene surfaces.52
Next, by substituting the d-phenylalanine moieties with either 3-iodo-d-tyrosine ([99mTc]TcO-4) or l-glutamic acid ([99mTc]TcO-5), a polar hydroxyl group and two carboxylate functions negatively charged at physiological pH were introduced in the linker of the PSMA ligands. Despite the presence of the polar hydroxyl group, 3-iodo-tyrosine is predicted to be more lipophilic than phenylalanine (clogP of −1.15 vs −1.56, calculated using ClogP within ChemDraw53) due to the 3-iodo-substituent. The aforementioned modifications led to a 1.7-fold ([99mTc]TcO-4: Kd = 8.4 ± 0.2 nM) and 2.4-fold ([99mTc]TcO-5: Kd = 6.1 ± 1.7 nM) increase in binding affinity compared to [99mTc]TcO-1. The nonspecific binding in the cell-based assay remained high for the 3-iodo-d-tyrosine-containing radioligand ([99mTc]TcO-4), but decreased significantly for the more polar bis-glutamyl derivative [99mTc]TcO-5 underlining high lipophilicity in the linker as the cause of nonspecific binding. No significant difference in the receptor-mediated internalization compared to [99mTc]TcO-1 was observed for both radioligands [99mTc]TcO-4 and [99mTc]TcO-5. The introduction of a desmethyl-BAT-chelator with a succinic acid unit in [99mTc]TcO-6 (Kd = 6.8 ± 0.5 nM) had no significant effect on the binding affinity toward PSMA, the internalization and the cell surface binding, when compared to [99mTc]TcO-5. In view of their differences in chain length and number of methyl groups, these similar results for [99mTc]TcO-5 and [99mTc]TcO-6 suggest that the chelator-part of the molecule is not involved in molecular interactions contributing to the radioligands binding affinity to a considerable extent. For all [99mTc]TcO-labeled PSMA radioligands evaluated in the internalization assays, the internalization (%AD/mg protein) was higher at 37 °C than at 4 °C, which is in accordance with previous reports13,54 and is pertinent for in vivo experiments.
With regard to their biodistribution, determined by quantitative SPECT or PET imaging in a LNCaP tumor xenograft mouse model, the radioligands investigated can be divided into two groups. The first group consists of [99mTc]TcO-1, -2, -3, and -4, and is characterized by low uptake in the tumor, mainly hepatobiliary excretion, and correspondingly low kidney uptake. Blood retention and liver uptake increased in the following order: [99mTc]TcO-1 < [99mTc]TcO-2 ≈ [99mTc]TcO-3 < [99mTc]TcO-4. This trend correlates to the lipophilicity of the amino acid residues incorporated in the linker of these 99mTc-labeled PSMA radioligands (none < Phe–Phe < Phe–3-I-Tyr). For the two epimers [99mTc]TcO-2 and [99mTc]TcO-3, a very similar biodistribution was observed, even though the latter, containing a d-Lysine moiety (R-configuration) in the linker, displayed a propensity toward higher blood retention and slower hepatobiliary excretion than [99mTc]TcO-2. Although internalization was increased when [99mTc]TcO-4 was compared to the parent compound [99mTc]TcO-1 in cell-based assays, similar tumor uptakes were observed for both radioligands in the xenograft mouse model.
The radioligands of the second group consisting of [99mTc]TcO-5 and [99mTc]TcO-6 as well as the clinical reference compounds [99mTc]Tc-PSMA-I&S and [68Ga]Ga-PSMA-11 displayed notably higher PSMA-dependent tumor uptake and mainly renal excretion. This was accompanied by a higher uptake in kidneys and parotid glands. Hence, the introduction of the negatively charged glutamic acids in the linker ([99mTc]TcO-5 and [99mTc]TcO-6) led to more favorable pharmacological properties, i.e. high tumor uptake and fast clearance from nontarget tissues leading to high tumor-to-background ratios, compared to the more lipophilic radioligands of the first group ([99mTc]TcO-1, -2, -3, and -4). This observation is in accordance with previous findings regarding the influence of negatively charged linker-moieties reported in the literature.55,56 Furthermore, [99mTc]TcO-5 with the bis(gem-dimethyl)-substituted BAT-chelator displayed higher tumor-to-background ratios (heart, kidneys, liver and muscle) than [99mTc]TcO-6 with the desmethyl-BAT-chelator and thus provided better tumor contrast for SPECT imaging. Hence, of the newly synthesized 99mTc-labeled PSMA radioligands, [99mTc]TcO-5 displayed the most advantageous properties for the intended use as a diagnostic agent for SPECT imaging of PCa. By blocking the sodium/iodide cotransporters with sodium perchlorate, remaining [99mTc]TcO4– in the preparations of [99mTc]TcO-5 was identified as the cause of the nonspecific uptake in submandibular/sublingual glands, thyroid gland and stomach wall. Future optimization of the synthesis procedure may address this issue, aiming for an almost complete conversion of [99mTc]TcO4–. Alternatively, in the clinic sodium perchlorate can be given to the patient prior to administration of a 99mTc-radiopharmaceutical preparation to prevent uptake of remaining [99mTc]TcO4– in the thyroid and the gastrointestinal tract.57,58 In vitro autoradiography on tissue cryosections from the LNCaP tumor xenograft mouse model confirmed the PSMA-dependent binding of [99mTc]TcO-5 to PSMA-positive cells in kidney cortex, salivary gland and tumor. The markedly lower tumor-to-off-target ratios observed in vivo by quantitative SPECT imaging compared to in vitro autoradiography indicate a significant tissue dependent influence of active uptake and retention of the radioligands, particularly in the kidney cortex. Hence, to better discriminate between binding based on PSMA-affinity, and active tissue uptake, as well as tissue clearance of the 99mTc-labeled PSMA radioligands in vivo, a direct comparison between in vitro and ex vivo autoradiography is recommended for upcoming preclinical studies.
The tumor uptake observed for [99mTc]TcO-5 was comparable to that observed for [99mTc]Tc-PSMA-I&S. It is important to note that the pharmacokinetic properties of [99mTc]TcO-5 were found to be more advantageous, with higher tumor-to-background ratios already 1 h after injection. Tumor-to-background ratios of [99mTc]TcO-5 and [99mTc]Tc-PSMA-I&S continued to increase within 4 h after injection reaching similar tumor contrast relative to blood and liver, while [99mTc]TcO-5 still provided higher tumor contrast relative to kidneys and most importantly to muscle. Co-administration of the high affinity PSMA-ligand 2-PMPA provided more efficient blockade of the kidney uptake of [99mTc]TcO-1 to -6 compared to [99mTc]Tc-PSMA-I&S. These results indicate that kidney uptake of [99mTc]TcO-1 to -6 is largely dependent on binding to PSMA expressed in the kidneys,59 whereas other mechanisms are probably involved in the case of [99mTc]Tc-PSMA-I&S. The inefficient blockade of [99mTc]Tc-PSMA-I&S uptake in kidneys of NMRI nude mice by 2-PMPA is in contrast to the significant blocking effect that has been observed previously in a biodistribution study in CB17 mice with severe combined immunodeficiency.15 This may result from “mass effects” of different amounts of free ligand in the radioligand preparations. The molar amounts in [99mTc]Tc-PSMA-I&S preparations administered for our SPECT imaging experiments were up to 16-fold higher compared to the formerly reported biodistribution study, possibly leading to stronger kidney uptake in the present experimental setting. However, also the competitor 2-PMPA was applied at a 7-fold higher molar dose in our SPECT experiments compared to the former biodistribution study raising the question why this increase still does not provide effective kidney blockade. Therefore, mouse strain-specific differences in the pharmacological fate of [99mTc]Tc-PSMA-I&S may have a role in differential kidney uptake and blocking efficiency.
Encouragingly, in the LNCaP xenograft mouse model [99mTc]TcO-5 performed similar to the established and regulatory approved PSMA–PET radioligand [68Ga]Ga-PSMA-11 displaying comparable tumor-to-background ratios 1 h after injection. Ultimately, the intraindividual diagnostic performance of the PSMA-SPECT radioligand [99mTc]TcO-5 in comparison to PSMA–PET radioligands, such as [68Ga]PSMA-11, has to be evaluated in clinical studies in the future.
In addition to the discussion of results from preclinical evaluation obtained for [99mTc]TcO-1 to -6, some particularities in the radioligands chemical structures are worth explaining: starting from the intermediate complex [99mTc]TcO-glucoheptonate, the ligand exchange of [99mTc][TcVO]3+ with 1-6 leads to a quaternization of the functionalized nitrogen atom and thus a chiral center is created at this nitrogen. This explains the formation of diastereomer in a 50:50 ratio, as detected during HPLC analysis, due to the chirality of the radioligand’s linker units and binding motif. This is consistent with literature reports for radioligands containing similar complexes of [99mTc][TcVO]3+ cores with N2S2-type chelators, functionalized via the chelator’s quaternary nitrogen atom, with [99mTc]TRODAT-1 being the most prominent example.60 Furthermore, regarding the orientation of the oxo-technetium-99m bond (in apical position of the distorted square-pyramidal structure of the [99mTc][TcVO]3+-N2S2 complex) relative to the functionalization at the quaternary nitrogen of the complex, two energetically distinct orientations, syn or anti, can occur. Hence, a total of 4 diastereomers are formed (Figure S11), whereas the most abundant pair of diastereomers is likely to have a syn-configuration. This has been consistently demonstrated for this type of chelator in other examples.61,62
Generally, diastereomeric compounds exhibit different physicochemical and pharmacological properties. Still, a significant influence of the different complex geometries on the affinity of the synthesized compounds for PSMA is unlikely: The strong interaction of the Glu-urea-Lys-motif with the S1’ glutamate pocket, the dinuclear ZnII active site and the S1-pocket of the PSMA protein already leads to high binding affinity - a binding mode that is shared by all ureido-based PSMA-ligands.10,27 This is in accordance with the rather similar PSMA-affinities of the radioligands [99mTc]TcO-1 to -6 measured within this study. Differences of the complex-isomers in distribution, metabolism and excretion cannot be ruled out by definition, but [99mTc]TcO-2 and [99mTc]TcO-3, which are diastereomers as well, displayed literally identical HPLC retention times and a similar imaging-derived biodistribution in the LNCaP xenograft mouse model. These findings suggest that possible differences regarding the pharmacological properties of the complex-isomers are rather small. Therefore, a more detailed structural analysis of the [99mTc]TcO-BAT-complex including isomer separation was beyond the scope of this study, but will be the subject of further work.
4. Conclusions
In the present work, we described the synthesis and biological characterization of six new 99mTc-labeled PSMA radioligands, which varied structurally in the linker and the chelator-part. While the introduced modifications had rather small influence on the PSMA binding affinity of the radioligands and the amount internalized into LNCaP cells, marked differences in the biodistribution of the radioligands in a LNCaP xenograft mouse model of PCa were observed. [99mTc]TcO-5, with a bis-glutamyl linker and a bis(gem-dimethyl)-substituted BAT-chelator, displayed the most advantageous properties for the intended use as a 99mTc-labeled PSMA radioligand for SPECT imaging of PCa: high and fast tumor uptake accompanied by rapid clearance from nontarget tissues resulting in favorable tumor-to-background contrast. [99mTc]TcO-5 displayed a faster pharmacokinetic profile than [99mTc]Tc-PSMA-I&S and performed similar to the established PSMA–PET radioligand [68Ga]Ga-PSMA-11. Further radiochemical optimization and preclinical characterization toward the clinical translation of [99mTc]TcO-5 (named [99mTc]TcO-ABX474) are warranted.
5. Experimental Section
5.1. Synthesis
5.1.1. General
Chemicals and protected amino acids for synthesis were purchased from Sigma-Aldrich (Taufkirchen, Germany), ABCR (Karlsruhe, Germany), Iris Biotech (Marktredwitz, Germany) and Carbolution (St. Ingbert, Germany). NMR spectra were recorded on a Bruker Avance Neo (500 MHz) spectrometer. NMR chemical shifts were referenced to the residual solvent resonances. All PSMA ligands, which were used as precursors for radiolabeling, were >95% pure by HPLC analysis.
5.1.2. Analytical Methods
The determination of the purity of the synthesized compounds was performed by HPLC using an Ultimate 3000 HPLC-System (Thermo Fisher Scientific, Bremen, Germany). Analyses were performed using an Ascentis Peptid Express ES-C18 column (150 mm × 4.6 mm, 2.7 μm; Supelco/Merck, Darmstadt, Germany) and a solvent system consisting of water (0.1% TFA) and ACN (0.1% TFA). A linear gradient from 5 to 100% ACN (0.1% TFA) in 10 min was applied. The flow rate was set to 1.5 mL/min.
LC–MS measurements were performed using an Ultimate 3000 HPLC system (Thermo Fisher Scientific) coupled to an ISQ EM (Thermo Fisher Scientific) or a MSQ Plus ESI Single Quadrupole mass spectrometer (Thermo Fisher Scientific). A Xselect Peptide CSH C18 (150 mm × 2.1 mm, 3.5 μm; Waters, Eschborn, Germany) column and a solvent system consisting of water (0.1% formic acid) and ACN (0.1% formic acid) were used. A linear gradient from 5% to 100% ACN (0.1% formic acid) in 15 min was applied. The flow rate was set to 0.4 mL/min.
HRMS measurements were performed using a Vanquish HPLC system (Thermo Fisher Scientific) hyphenated to a Q-Exactive plus orbitrap mass spectrometer (Thermo Fisher Scientific). Chromatographic separation was performed on a Ascentis Express C18 column (150 mm × 2.1 mm, 2.7 μm; Supelco/Merck). The solvent system consisted of water (0.1% formic acid) and ACN (0.1% formic acid). A linear gradient elution was conducted by using 2% ACN (0.1% formic acid) for 2 min, linearly increasing to 90% ACN (0.1% formic acid) within 23 min. The solution was then held for 4 min and re-equilibrated with 2% ACN (0.1% formic acid) for 5 min. The total run time was 34 min with a flow rate of 0.2 mL/min. Column and autosampler temperatures were 30 and 10 °C, respectively. All samples were analyzed using the positive electrospray ionization (ESI) mode. Each sample was injected in duplicates with same source settings. The source settings were optimized as follows: sheath gas flow rate, 30 arbitrary units; auxiliary gas flow rate, 10 arbitrary units; spray voltage, 3.3 kV; S-lens, 50 arbitrary units; capillary temperature, 100 °C; and auxiliary heater temperature, 100 °C. Full MS scan data were obtained from m/z 300 to 2000 at a resolution of 70,000 with the AGC target of 3 × 106. Microscans were set to 1. The AGC target was set to 1 × 105, the intensity threshold to 8 × 103, with the maximum injection time of 50 ms. The precursor ions were filtered by the quadrupole, which operated at an isolation window of m/z 4.
5.1.3. Synthesis of Reagents
5.1.3.1. Di-tert-butyl (1H-imidazole-1-carbonyl)-l-glutamate (8)
H-Glu(OtBu)-OtBu · HCl (1.479 g, 5.00 mmol, 1 equiv), DMAP (0.030 g, 0.250 mmol, 0.05 equiv) and triethylamine (1.74 mL, 12.50 mmol, 2.5 equiv) were dissolved in 50 mL dry DCM under argon atmosphere and the solution was cooled to 0 °C in an ice–water bath. CDI (0.892 g, 5.50 mmol, 1.1 equiv) was added and the reaction was stirred at r.t for 5 h. The reaction was quenched with NaHCO3 (30 mL) and the phases were separated. The organic layer was washed with water (2 × 30 mL) and brine (30 mL). The organic layer was dried over Na2SO4 and the solvent was evaporated in vacuo. Purification by column chromatography (n-hexane/ethyl acetate, 1:2, v/v) gave di-tert-butyl (1H-imidazole-1-carbonyl)-l-glutamate (8) as a colorless oil (1.417 g, 80%). MS(ESI): Calculated monoisotopic mass (C17H27N3O5): 353.2; found: m/z = 354.2 [M + H]+. 1H NMR (500 MHz, CDCl3) δ 8.16 (t, J = 1.1 Hz, 1H), 7.44 (d, J = 6.6 Hz, 1H), 7.40 (t, J = 1.6 Hz, 1H), 7.11–7.07 (m, 1H), 4.44 (ddd, J = 7.9, 6.6, 4.1 Hz, 1H), 2.53–2.36 (m, 2H), 2.25–2.02 (m, 2H), 1.49 (s, 9H), 1.44 (s, 9H).
5.1.4. Peptide Synthesis Procedures
Fmoc/tBu-based solid phase peptide synthesis was carried out on 0.5 to 1 mmol scale in a syringe containing a frit disc and shaken on a multivortexer (Heidolph multi Reax, Schwabach, Germany) at speed 8. Dde was used as orthogonal protecting group for amino groups. Nonreacting carboxylic acids were protected with tBu-groups. Fmoc-3-I-d-Tyr was used without side chain protection. Other building blocks were used as indicated in Schemes 1 and 2. Preparative RP-HPLC was performed on a puriFlash 4100 (InterChim, Montluçon Cedex, France) using a Gemini NX-C18 column (250 mm × 50 mm, 10 μm; Phenomenex, Aschaffenburg, Germany). Linear gradients of water (0.1% TFA) and ACN (0.1% TFA) were applied.
5.1.4.1. 2-CTC-Resin Loading (GP1)
Loading of the 2-chlorotrityl chloride resin (100–200 mesh), 1% DVB (2-CTC) resin with a Fmoc-protected amino acid (Fmoc-aa–OH) was carried out by stirring a solution of the 2-CTC-resin (1.55 mmol/g) and Fmoc-aa–OH (2 equiv) in anhydrous DCM with DIPEA (6 equiv) at room temperature for 3 h. Remaining trityl chloride was capped by the addition of a capping solution (DCM/MeOH/DIPEA (80:15:5, v/v/v, 5 mL/g resin) for 30 min. Afterward, the resin was filtered and washed with DCM (2 × 5 mL/g resin), DMF (2 × 5 mL/g resin), isopropanol (5 mL/g resin), Et2O (5 mL/g resin) and dried. Final loading of Fmoc-aa–OH was determined by the following equation:
Whereas m2 = mass of loaded resin [g]; m1 = mass of unloaded resin [g]; MW = molecular weight of aa [g/mol]; MHCl = molecular weight of HCl [g/mol].
5.1.4.2. On-Resin Amide Bond Formation (GP2)
-
1.
The solution of protected Fmoc-aa–OH (2 equiv), HATU (2 equiv), HOAt (2 equiv), DIPEA (5.6 equiv) in DMF (10 mL/g resin) was added to the resin bound free amine peptide and shaken for 2 h at r.t. After reaction, the coupling mixture was drained and the resin was washed with DMF (5 × 5 mL/g resin).
-
2.
The solution of protected Fmoc-aa–OH (2 equiv), PyBOP (2 equiv), HOBt (2 equiv), DIPEA (2 equiv) in DMF (10 mL/g resin) was added to the resin bound free amine peptide and shaken for 2 h at r.t. After reaction, the coupling mixture was drained and the resin was washed with DMF (5 × 5 mL/g resin).
5.1.4.3. On-Resin Fmoc-Deprotection (GP3)
The resin bound Fmoc protected peptide was treated with 20% piperidine in DMF (v/v, 8 mL/g resin) for 15 min and subsequently for another 15 min. The resin was later washed with DMF (5 × 5 mL/g resin).
5.1.4.4. On-Resin Dde-Deprotection (GP4)
The resin bound Dde protected peptide was treated with 2% hydrazine monohydrate in DMF (v/v, 5 mL/g resin) for 30 min. The resin was later washed with DMF (5 × 5 mL/g resin).
5.1.4.5. On-Resin Activation of Carboxylic Acid (GP5)
The resin bound peptide with free carboxylic acid was treated with a mixture of TSTU (2 equiv) and DIPEA (2 equiv) in DMF (10 mL/g resin) at r.t for 30 min to 1 h. The NHS ester formation was monitored by RP-HPLC. After the completion of reaction, the resin was washed with DMF (5 × 5 mL/g resin).
5.1.4.6. On-Resin Conjugation of the Chelator to the Peptide (GP6)
-
1.
For conjugation of the protected chelator building block 7 to the free amine on resin, 7 was preactivated with PyBOP (2 equiv) and DIPEA (2 equiv) as base in DMF for 5 min and then added to the swollen resin and shaken for 2 h at r.t. The completion of reaction was monitored by analytical HPLC. After reaction, resin was washed with DMF (5 × 5 mL/g resin).
-
2.
For conjugation of the protected chelator building block 9 to the free carboxylic acid on resin the free acid was activated according to GP5. After the formation of the NHS ester, resin bound peptide was treated with 9 (1 equiv) and DIPEA (2 equiv) in DMF for 2 h.
5.1.4.7. Urea Formation (GP7)
The free amine was treated with (1H-imidazole-1-carbonyl)-l-glutamate (8) (3 equiv) and NMM (3 equiv) in DMF for 2 h at r.t. After reaction, the coupling mixture was drained and the resin was washed with DMF (5 × 5 mL/g resin).
5.1.4.8. Deprotection and Cleavage from the Resin (GP8)
After the completion of all couplings the resin was washed with DMF (3 × 5 mL/g), DCM (3 × 5 mL/g), isopropanol (3 × 5 mL/g), and Et2O (3 × 5 mL/g).
-
1.
The fully protected resin-bound peptide was treated with a mixture of TFA/TIS/H2O (95/2.5/2.5, v/v/v) and shaken for 1 to 2 h at r.t. The solution was filtered off and concentrated in vacuo. The crude peptide was precipitated from ice-cold Et2O. The crude peptide was dissolved in a mixture of ACN/H2O (4:6, v/v) and lyophilized. To cleave the PMB groups the residue was treated with a cold solution of anisole (2 equiv) in TFA. Hg(OAc)2 (2 equiv) was added and the reaction mixture was stirred for 30 min at r.t. TFA was removed in vacuo. The residue was triturated three times with Et2O and subsequently dissolved in EtOH. Hydrogen sulfide was bubbled through the solution for 15 min and the reaction mixture was filtered through a pad of Celite. The filtrate was concentrated in vacuo to give the crude product. The crude peptide was purified via preparative RP-HPLC to give the pure compound as TFA-salt (white to off-white solid).
-
2.
The fully protected resin-bound peptide was treated with a mixture of TFA/TIS/EDT/H2O (92.5/2.5/2.5/2.5, v/v/v/v) at 0 °C and stirred for 1 to 2 h at 0 °C to r.t. The deprotection was monitored by analytical HPLC. 10% TFMSA was added dropwise to above reaction mixture at 0 °C under argon atmosphere over a period of 10 min. The cleavage of PMB was monitored by analytical HPLC. After the completion of reaction, the crude peptide was precipitated from ice-cold Et2O and dissolved in a mixture of ACN/H2O (30/70, v/v) and lyophilized. The crude peptide was purified via preparative RP-HPLC to give the pure compound as TFA-salt (white to off-white solid).
5.1.5. Synthesized PSMA Ligands
5.1.5.1. (3S,7S,26S)-38-mercapto-33-(2-mercapto-2-methylpropyl)-38-methyl-5,13,20,28-tetraoxo-4,6,12,21,27,33,36-heptaazanonatriacontane-1,3,7,26-tetracarboxylic Acid (1)
HPLC: tR = 4.02 min, 95.7%; MS(ESI): Calculated monoisotopic mass (C41H75N7O12S2): 921.49; found: m/z 922.45 [M + H]+, 462.00 [M + 2H]2+; HRMS(ESI): Calculated monoisotopic mass (C41H75N7O12S2): 921.4915; found: m/z 922.4981 [M + H]+, 461.7538 [M + 2H]2+.
5.1.5.2. (3S,7S,26S,29R,32R)-29,32-dibenzyl-44-mercapto-39-(2-mercapto-2-methylpropyl)-44-methyl-5,13,20,28,31,34-hexaoxo-4,6,12,21,27,30,33,39,42-nonaazapentatetracontane-1,3,7,26-tetracarboxylic Acid (2)
HPLC: tR = 6.83 min, 98.3%; MS(ESI): Calculated monoisotopic mass (C59H93N9O14S2): 1215.63; found: m/z 1216.64 [M + H]+, 608.56 [M + 2H]2+. HRMS(ESI): Calculated monoisotopic mass (C59H93N9O14S2): 1215.6283; found: m/z 1216.6361 [M + H]+, 608.8239 [M + 2H]2+.
5.1.5.3. (3S,7S,26R,29R,32R)-29,32-dibenzyl-44-mercapto-39-(2-mercapto-2-methylpropyl)-44-methyl-5,13,20,28,31,34-hexaoxo-4,6,12,21,27,30,33,39,42-nonaazapentatetracontane-1,3,7,26-tetracarboxylic Acid (3)
HPLC: tR = 6.83 min, 98.6%; MS(ESI): Calculated monoisotopic mass (C59H93N9O14S2): 1215.63; found: m/z 1216.70 [M + H]+, 609.62 [M + 2H]2+; HRMS(ESI): Calculated monoisotopic mass (C59H93N9O14S2): 1215.6283; found: m/z 1216.6362 [M + H]+, 608.8238 [M + 2H]2+.
5.1.5.4. (3S,7S,26R,29R,32R)-29-benzyl-32-(4-hydroxy-3-iodobenzyl)-44-mercapto-39-(2-mercapto-2-methylpropyl)-44-methyl-5,13,20,28,31,34-hexaoxo-4,6,12,21,27,30,33,39,42-nonaazapentatetracontane-1,3,7,26-tetracarboxylic Acid (4)
HPLC: tR = 5.22 min, 96.5%; MS(ESI): Calculated monoisotopic mass (C59H92IN9O15S2): 1357.52; found: m/z 1358.52 [M + H]+, 679.88 [M + 2H]2+; HRMS(ESI): Calculated monoisotopic mass (C59H92IN9O15S2): 1357.5199; found: m/z 1358.5249 [M + H]+, 679.7687 [M + 2H]2+.
5.1.5.5. (3S,7S,26R,29S,32S)-29-(2-carboxyethyl)-32-(5-((2-mercapto-2-methylpropyl)(2-((2-mercapto-2-methylpropyl)amino)ethyl)amino)pentanamido)-5,13,20,28,31-pentaoxo-4,6,12,21,27,30-hexaazatetratriacontane-1,3,7,26,34-pentacarboxylic Acid (5)
HPLC: tR = 3.97 min, 99.7%; MS(ESI): Calculated monoisotopic mass (C51H89N9O18S2): 1179.58; found: m/z 1180.51[M + H]+, 590.64 [M + 2H]2+; HRMS(ESI): Calculated monoisotopic mass (C51H89N9O18S2): 1179.5767; found: m/z 1180.5829 [M + H]+, 590.7976 [M + 2H]2+; 1H NMR (400 MHz, D2O) δ 4.45 (dd, J = 8.8, 5.5 Hz, 1H), 4.34 (dd, J = 8.8, 5.5 Hz, 2H), 4.28 (dd, J = 9.0, 5.2 Hz, 1H), 4.20 (dd, J = 8.7, 5.0 Hz, 1H), 3.82–3.88 (m, 2H), 3.69–3.75 (m, 2H), 3.50 (s, 2H), 3.35–3.42 (m, 2H), 3.30 (s, 2H), 3.15–3.22 (m, 4H), 2.48–2.55 (m, 6H), 2.41 (t, J = 7.0 Hz, 2H), 2.23 (t, J = 6.9 Hz, 4H), 2.06–2.19 (m, 3H), 1.95–2.05 (m, 3H), 1.79–1.93 (m, 4H), 1.64–1.79 (m, 4H), 1.53–1.63 (m, 8H), 1.53 (s, 6H), 1.48 (s, 6H), 1.34–1.46 (m, 4H), 1.26–1.33 (m, 4H); 13C NMR (101 MHz, D2O) δ 177.23, 177.14, 176.93, 176.89, 176.83, 176.28, 176.00, 175.57, 173.44, 172.91, 163.14, 162.79, 159.26, 117.77, 114.87, 67.31, 60.79, 56.47, 53.23, 52.90, 52.83, 52.61, 51.41, 42.49, 41.75, 41.15, 38.90, 38.88, 35.70, 34.27, 30.64, 30.12, 30.04, 29.83, 29.60, 29.13, 27.79, 27.73, 27.71, 26.32, 26.11, 25.22, 22.54, 22.34, 22.31, 21.84.
5.1.5.6. (3S,7S,26R,29S,32S)-29-(2-carboxyethyl)-32-(4-((3-((2-mercaptoethyl)(2-((2-mercaptoethyl)amino)ethyl)amino)propyl)amino)-4-oxobutanamido)-5,13,20,28,31-pentaoxo-4,6,12,21,27,30-hexaazatetratriacontane-1,3,7,26,34-pentacarboxylic Acid (6)
HPLC: tR = 3.52 min, 95.1%; MS(ESI): Calculated monoisotopic mass (C49H84N10O19S2): 1180.54; found: m/z 1181.53 [M + H]+, 591.36 [M + 2H]2+; HRMS(ESI): Calculated monoisotopic mass (C49H84N10O19S2): 1180.5356; found: m/z 1181.5434 [M + H]+, 591.2768 [M + 2H]2+.
5.2. Radiochemistry
5.2.1. General
Stannous chloride, d-mannitol, and calcium α-d-glucoheptonate dihydrate were purchased from Sigma-Aldrich Chemie GmbH. HCl (1 N) and PBS (Dulbecco’s Phosphate Buffered Saline, without calcium and magnesium) were purchased from Fisher Scientific GmbH (Schwerte, Germany). Saline (0.9% NaCl, sterile) was purchased from AppliChem GmbH (Darmstadt, Germany). [99mTc]NaTcO4 was obtained from a 99Mo/99mTc generator (PERTECTOR 2.3-57.1 GBq Radionuklidgenerator, Radioisotope Centre POLATOM, Otwock, Poland). For conducting in vitro stability tests the following instruments were used: thermoshaker BioShake iQ (QUANTIFOIL Instruments, Jena, Germany), centrifuge Centrifuge 5424 (Eppendorf, Hamburg, Germany), and gamma counter Wallac 1480 Wizard 3” (PerkinElmer, Boston, MA, USA).
5.2.2. Analytical Methods
Radio-high-performance phase liquid chromatography (radio-HPLC) was performed on a JASCO X-LC system (JASCO Labor- und Datentechnik GmbH, Pfungstadt, Germany) equipped with a UV/vis detector UV-2070 (monitoring at 205 nm) and a radioactivity flow detector GABI Star (raytest Isotopenmessgeräte, Straubenhardt, Germany) including NaI detector (2” × 2” pinhole, 16 mm × 30 mm). Analyses were performed using a Poroshell 120 EC-C18 column (100 mm × 3 mm, 3.5 μm; Agilent Technologies Deutschland GmbH, Waldbronn, Germany) and a solvent system consisting of water (0.1% TFA) and ACN (0.1% TFA). Two different linear gradient elution methods were used: (method A) 0–0.5 min 0%, 0.5–3 min 0–100%, 3–5 min 100%, 5–8 min 0% ACN (0.1% TFA); flow rate: 0–0.5 min 0.4 mL/min, 0.5–8 min 0.7 mL/min and (method B) 0–1.5 min 0%, 1.5–10 min 0–100%, 10–12 min 100%, 12–15 min 0% ACN (0.1% TFA); flow rate: 0.7 mL/min; as well as isocratic elution methods using a particular percentage of ACN (0.1% TFA) appropriate for the respective radioligand.
Radio-thin layer chromatography (radio-TLC) was performed on silica gel TLC sheets (POLYGRAM SIL G UV254, Macherey-Nagel, Düren, Germany) using MeOH/NH4OAc (2M) 1:1 (v/v). Detection was carried out using storage phosphor screens BAS-IP MS 2025 (Fujifilm Co., Tokyo, Japan) and an CR-25 Bio image plate scanner (Elysia s.a., Angieur, Belgium).
5.2.3. Radiolabeling with Technetium-99m
To ensure an exclusion of oxygen, HCl (1N) as well as water were purged with a stream of He for 15 min. The respective PSMA ligand (1.0 mg; 1-6) was dissolved in 50 μL abs. EtOH and 950 μL water. Calcium α-d-glucoheptonate dihydrate (10 mg) and d-mannitol (5 mg) were dissolved in water (10 and 1.0 mL, respectively). Stannous chloride (10 mg) was dissolved in 10 mL HCl (1N) and the resulting solution was diluted two times with water 1:10 to obtain the solution (0.01 μg/mL), which was used in the following. For the radiolabeling 10 μL of the calcium α-d-glucoheptonate solution (10 μg), 200 μL of the d-mannitol solution (1 mg), 50 μL of the PSMA ligand solution (50 μg) and 0.5 mL NaCl (0.9%) were mixed. After addition of 0.5 mL [99mTc]NaTcO4 (0.02–7 GBq) in NaCl (0.9%) and 100 μL stannous chloride solution (1 μg), the well mixed reaction mixture (pH 5–6.5) was kept at r.t. for 20 min and finally at 80 °C for another 20 min. After cooling, the product was ready for further use. The reaction was monitored by radio-HPLC (method A) and the RCY was determined. Similarly, the RCP of the product was determined by radio-HPLC (methods A and B) and the absence of 99mTc/99Tc-colloid formation was confirmed by radio-TLC. The average RCP of 99mTc-labeled PSMA radioligands used for biological studies was >90%, except for [99mTc]TcO-4 (89.8%).
5.2.4. Stability in Saline (0.9% NaCl) and PBS
The freshly produced radioligand solution (10–20 MBq, 20–100 μL) was added to the respective medium (200–400 μL), vortexed quickly, and shaked gently at 25 °C. After 1, 2, 4, and 20 h samples were taken and analyzed by radio-HPLC (method A).
5.2.5. Stability in Native Plasma from CD-1 Mouse and Human
Plasma was collected on the same day and stored on ice within 3 h until use. Stability tests were conducted at 37 °C for up to 6 h, similar to the procedure described in Section 5.2.4. At the defined time points samples were taken and added to a 4-fold volume of an ice-cold mixture of MeOH/H2O (4:1, v/v). After intensive shaking (5 min) and centrifugation (14,000 rpm, 10 min), the supernatants were separated and inspected by radio-HPLC. Efficiencies of the extractions were calculated after activity measurement of aliquots of the supernatants and the corresponding residues by gamma counter using the following equation:
5.2.6. 68Ga-Labeling of PSMA-11
A 68Ga generator was purchased from iThemba LABS (Cape Town, Republic of South Africa). PSMA-11 (4–8 μg ≙ 4.2–8.4 nmol; ABX advanced biochemical compounds GmbH, Radeberg, Germany) was labeled with 68GaCl3 (150 to 250 MBq) in 400 μL ammonium acetate (2 M) and HCl at pH 4.5. The reaction mixture was incubated for 10 min at 90 °C. Quality control was carried out using HPLC (semipreparative Zorbax 300SB-C18, 250 mm × 9.4 mm, 5 μm; Agilent Technologies, Santa Clara, CA, USA). The radiochemical yield for [68Ga]Ga-PSMA-11 was >97% with average molar activities of 30 to 60 GBq/μmol.
5.3. Cell-Based Assays
5.3.1. Cell Culture
Binding assays were performed using the cell lines LNCaP (ATCC: CRL-1740, CLS GmbH, cryovial 300265, received Aug 2018, last cell line authentication Dec. 2022 by 17 short tandem repeat (STR), last test for negative mycoplasmas March 21, 2024), which highly expresses PSMA, and PSMA-negative PC3 (ATCC: CRL-1435, received Dec 2010, last authentication Dec 2017 by STR, last test for negative mycoplasmas March 21, 2024). The cells were cultured as a monolayer at 37 °C in a humidified atmosphere with 5% CO2 and 95% air, using RPMI medium (GIBCO) supplemented with 10% fetal calf serum (Biochrom AG, Berlin, Germany). Once the cells reached confluency, they were washed twice with PBS and detached using trypsin/EDTA (0.05%/0.02%). The cells were then suspended in the medium and counted (Casy TT, Omni Life Science, Germany). Two days before the assays, LNCaP and PC3 cells were seeded in 24-well plates, 1 × 105 cells/well.
5.3.2. Saturation Assays
After aspirating the medium from the cells, 100 μL of PBS (three samples each for total binding) and in adjacent wells 100 μL of 2-(phosphonomethyl)pentanedioic acid63 (2-PMPA, final concentration 100 μM, two samples each for nonspecific binding; ABX advanced biochemical compounds GmbH) was pipetted onto the cell lawn. Simultaneously, 400 μL of medium including 8 concentrations (0.3 to 40 nM) of the 99mTc-labeled PSMA radioligands ([99mTc]TcO-1 to -6) and the reference compound ([68Ga]Ga-PSMA-1164) was added. After incubation at 37 °C for 1 h, the supernatants were aspirated, the cells washed twice with cold PBS and the cell lawn lysed with 500 μL NaOH/SDS (0.1 M/1%) by shaking (3 to 5 min at r.t.). After transferring the lysates into measuring tubes, the activity of the samples was measured in a gamma counter (2480 Automatic Gamma Counter Wizard 2, PerkinElmer). The protein content of the lysed samples was determined using a spectrophotometer (NanoDrop, Thermo Fisher Scientific, USA) at an absorbance of 280 nm. Affinity constants (Kd) and binding capacities (Bmax) were calculated by fitting the data using the nonlinear curve fitting program (Prism 9, GraphPad Software). Two experiments were conducted with [99mTc]TcO-2, -3, -4 and [68Ga]Ga-PSMA-11, three with [99mTc]TcO-1 and four with [99mTc]TcO-5. One assay was performed with [99mTc]TcO-6.
5.3.3. Internalization Assays
After aspirating the medium from the cells, 100 μL PBS (three samples each for the total part) and in adjacent wells 100 μL 2-PMPA (final 100 μM, two samples each for the nonspecific part) were pipetted onto the cell lawn, followed by 400 μL medium including the corresponding 99mTc-labeled PSMA radioligand (final 25 nM). Samples were incubated for 1 h at 4 °C and neighboring samples at 37 °C. The surface-bound activity was stripped with 4 °C-cold acid-wash buffer (0.2 M glycine, 0.15 M NaCl, pH 2.8) for 5 min. The acid wash buffer samples were transferred from the plate wells to measuring tubes, as was the PBS buffer after washing once (binding on the surface). Cytosolic activity was determined by detaching the cells with lysis buffer NaOH/SDS (0.1 M/1%) (3 to 5 min). Cell surface and cytosolic activity were measured separately in a gamma counter. For evaluation of the bound and internalized part of the [99mTc]TcO-labeled PSMA radioligands, the protein content from the cell lysates was determined (see above). Two experiments were conducted with [99mTc]TcO-1, [99mTc]TcO-4 and [68Ga]Ga-PSMA-11 and four with [99mTc]TcO-5. One assay was performed with [99mTc]TcO-6.
5.4. In Vivo Studies
5.4.1. General Animal Experimentation
All animal experiments were carried out according to the guidelines of the German Regulations for Animal Welfare and have been approved by the local Ethical Committee for Animal Experiments (reference number: DD24.1-5131/499/49). A prostate cancer xenograft model was generated via subcutaneous injection of 5 × 106 human LNCaP cells into the right shoulder of 8–12-week-old male nude mice (Rj:NMRI-Foxn1nu/nu, Janvier Labs, Le Genest-Saint-Isle, France). Imaging studies with radiotracers were performed when tumors had reached a diameter of >6 mm. If required, activity of sodium/iodine symporters was blocked with sodium perchlorate (Irenat, Sigmapharm Arzneimittel, Vienna, Austria), administered intraperitoneally in 0.2 mL of PBS at a dose of 10 mg 1 h before radioligand injection. Prior to imaging procedures, anesthesia was induced and maintained with inhalation of 10% (v/v) desflurane in 30/10% (v/v) oxygen/air. During anesthesia, animals were continuously warmed at 37 °C. PSMA specificity of radioligands was tested indirectly by blocking specific binding sites with 2-PMPA (ABX advanced biochemical compounds GmbH), administered simultaneously with the radioligands at a dose of 1.5 mg. Characteristics of radiotracer preparations and animal cohorts included in investigations on functional imaging are provided as Supporting Information (Table S3).
5.4.2. SPECT Imaging
Each animal received a single dose of 99mTc-labeled radioligand ([99mTc]TcO-1 to -6 and the reference radioligand [99mTc]Tc-PSMA-I&S15) with an initial activity of 30 MBq delivered in 0.2 mL of PBS through injection into a tail vein. Single-photon emission computed tomography (SPECT) was performed using the Mediso NanoScan SPECT/CT (Mediso Medical Imaging Systems, Budapest, Hungary) equipped with the APT63 aperture consisting of four M3 multipinhole collimators. Image recording was started within the following time windows after radioligand injection (with corresponding scan times): 0.75–1.25 h (30 min), 3–4 h (60 min), 19–21 h (120 min). Three-dimensional list mode data were binned within the 20% energy window of the 140.5 keV photopeak. With each SPECT scan, a corresponding CT image was recorded and used for anatomical referencing and attenuation correction. SPECT images were reconstructed using the Tera-Tomo three-dimensional algorithm at normal dynamic range with a voxel size of 0.4 mm applying corrections for scatter, attenuation, and decay.
5.4.3. PET Imaging
Each animal received a single dose of the reference radioligand [68Ga]Ga-PSMA-1164 with an initial activity of 8 MBq delivered in 0.2 mL of Dulbecco’s phosphate-buffered saline as an intravenous injection through a tail vein catheter. Positron emission tomography (PET) was performed using the nanoScan PET/CT (Mediso Medical Imaging Systems). With each PET scan, a corresponding CT image was recorded and used for anatomical referencing and attenuation correction. Emission of the annihilation photons was recorded continuously upon radiotracer injection for 60 min at a coincidence mode of 1:5. Three-dimensional list mode data were binned using the 400–600 keV energy window. PET images of the 40–60 min time frame were reconstructed using the Tera-Tomo three-dimensional algorithm with a voxel size of 0.4 mm applying corrections for random events, scatter, attenuation, and decay.
5.4.4. Quantitative Image Analysis
SPECT and PET images were postprocessed and analyzed using Rover (ABX Advanced Biochemical Compounds GmbH) and displayed as maximum intensity projections. Tissue-specific regions of interest (ROIs) were generated using fixed intensity thresholds for delineation of gall bladder (50%), heart (0%), kidneys (20%), liver (0%, partial region), muscle (0%, partial region), parotid glands (50%), submandibular/sublingual glands (30%), thyroid gland (30%), total body (0%), tumor (30%), and urinary bladder (10%), as well as manually adjusted thresholds for delineation of intestine and stomach wall. Radioligand concentrations and amounts were extracted as standardized uptake values (SUV) normalized to body weight. The highest concentration spot in a tissue was determined as the highest voxel intensity detected within the ROI (tissue-specific SUVmax). The proportion of initial dose that was taken up in a tissue was determined as the total intensity within the ROI (tissue-specific SUVtotal) divided by the total intensity initially distributed within the entire animal (initial whole-body SUVtotal = body weight). The total intensity of the liver was extrapolated from a partial ROI using the organ weight from a realistic dosimetry model for 35-g-mice65 as implemented in Olinda 2.2.3 (Hermes Medical Solutions AB, Stockholm, Sweden).
5.4.5. Statistical Analysis
Statistical analysis was performed using Prism 10 (GraphPad Software). If not stated otherwise, data are presented as means with standard deviation and n represents the number experiments. Significance of differences was tested using ANOVA with Fisher’s LSD test. Differences were considered significant at P-values <0.05.
5.5. Autoradiographic Studies for [99mTc]TcO-5
For quantitative autoradiography 10 μm cryosections of kidney, glandula submandibularis and LNCaP tumor (each n = 3) of LNCaP tumor bearing mice (same xenograft mouse model as used for SPECT imaging, see 7.4.1) were thawed, dried, and preincubated with incubation buffer (50 mM TRIS-HCl, pH 7.4, 100 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 1% BSA) for 10 min, dried under an airstream and subsequently incubated with the incubation buffer containing 509 kBq/mL [99mTc]TcO-5 alone or together with 10 μM of the reference compound or 2-PMPA to assess nonspecific binding of [99mTc]TcO-5 for 2 h, washed twice for 2 min with ice-cold 50 mM Tris HCl buffer, pH7.4 and 10 s in double-distilled water, afterward dried under an airstream and finally the slides were exposed to a phosphor imager plate (BAS-IP TR2025, Fujifilm Corporation) for 2 h in a dark chamber. After scanning at high sensitivity and a resolution of 12.5 μm with a CR35 Bio image plate scanner (Raytest Isotopenmessgeräte GmbH, Straubenhardt, Germany) the analysis of the autoradiographic images were performed with the AIDA 5.1 software (Elysia-Raytest, Angleur, Belgium).
Acknowledgments
The authors greatly acknowledge the excellent technical assistance of Andrea Suhr, Julia Aldinger, and Mareike Barth (HZDR). The authors thank the head and staff of the animal research facility, Birgit Belter, Ph.D., and Helge Gläser (HZDR). Furthermore, the authors thank Jan Mollitor (Zittau/Görlitz University of Applied Sciences) for NMR studies and Alexander Milentyev (ABX GmbH) for the collection of HRMS data.
Glossary
Abbreviations
- 2-PMPA
2-(phosphonomethyl)pentanedioic acid
- AD
administered dose
- BAT
bis(aminoethanethiol)
- CDI
1,1′-carbonyldiimidazole
- DADT
diaminodithiol
- Dde
1-(4,4-dimethyl-2,6-dioxocyclohex-1-yliden)ethyl
- DIPEA
N,N-diisopropylethylamine
- EDT
1,2-ethanedithiol
- HATU
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
- HOAt
1-hydroxy-7-azabenzotriazole
- HOBt
1-hydroxybenzotriazol
- HYNIC
6-hydrazinonicotinamide
- MAMA
monoamino-monoamide dithiol
- NMM
4-methylmorpholine
- PCa
prostate cancer
- PET
positron emission tomography
- PSMA
prostate specific membrane antigen
- PyBOP
benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
- RCP
radiochemical purity
- RCY
radiochemical yield
- ROI
region of interest
- SPECT
single photon emission computer tomography
- SUV
standardized uptake value
- TFMSA
trifluoromethanesulfonic acid
- TIS
triisopropylsilane
- TSTU
O-(N-succinimidyl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate
Supporting Information Available
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02767.
Schemes showing the synthesis of the PMB-protected bifunctional BAT-chelator building blocks 7 and 9; exemplary radio-HPLC chromatograms for 99mTc-labeled PSMA radioligand preparations and in vitro stability studies; radio-TLC analyses after radiosynthesis; saturation graphs for cell-based assays using LNCaP and PC3 cells; graphical representation of the results of the internalization assays; SPECT images of 99mTc-labeled PSMA radioligands in LNCaP tumor-bearing mice in the presence of the competitor 2-PMPA; scheme showing stereoisomers of the [99mTc]TcO-BAT-complex; summary of radiolabeling batch sizes and radioanalytical data; efficiency of extraction after protein precipitation from plasma; radioligand preparations and animal cohorts included in investigations on functional imaging; HPLC-chromatograms and HRMS-spectra of 1-6; and NMR spectra and assignments for 5 (PDF)
Molecular formula strings (CSV)
Author Contributions
¶ C.L. and F.-A.L. contributed equally to this work. S.F. and M.U. contributed equally to this work. Organic chemistry: C.L., H.-J.L., D.J., and C.M.; radiochemistry: F.-A.L. and S.F.; cell-based assay: W.S.; autoradiography: D.G.; in vivo studies: M.U.; resources and project administration: K.K., J.P., P.B., and A.H.; original draft preparation: C.L. and F.-A.L., with the support of M.U., W.S., D.G., and S.F. All authors revised the manuscript and gave approval to the final version.
This work was funded by European Regional Development Fund (ERDF) of the European Union (EU) and from tax funds based on the budget passed by the Saxon State Parliament (Sächsische Aufbaubank: 100363651, 100363946).
The authors declare the following competing financial interest(s): The authors Christian Lis., Friedrich-Alexander Ludwig, Steffen Fischer, Martin Ullrich, Hans-Joachim Lankau, Wiebke Sihver, Desna Joseph, Christoph Meyer and Alexander Hoepping are inventors of related patent applications (WO2023/227535, EP4282438). Christian Lis, Hans-Joachim Lankau, Desna Joseph, Christoph Meyer and Alexander Hoepping are/were employees of ABX Advanced Biochemical Compounds GmbH, Radeberg. Klaus Kopka is co-inventor of the PSMA ligands PSMA-617, PSMA-914, and PSMA-1007.
Supplementary Material
References
- https://www.wcrf.org/cancer-trends/worldwide-cancer-data/ (accessed Oct 01, 2024).
- Pernar C. H.; Ebot E. M.; Wilson K. M.; Mucci L. A. The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspect. Med. 2018, 8 (12), a030361 10.1101/cshperspect.a030361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Horoszewicz J. S.; Kawinski E.; Murphy G. P. Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients. Anticancer Res. 1987, 7 (5b), 927–935. [PubMed] [Google Scholar]
- Silver D. A.; Pellicer I.; Fair W. R.; Heston W. D.; Cordon-Cardo C. Prostate-Specific Membrane Antigen Expression in Normal and Malignant Human Tissues. Clin. Cancer Res. 1997, 3 (1), 81–85. [PubMed] [Google Scholar]
- Ghosh A.; Heston W. D. W. Tumor Target Prostate Specific Membrane Antigen (PSMA) and its Regulation in Prostate Cancer. Journal of Cellular Biochemistry 2004, 91 (3), 528–539. 10.1002/jcb.10661. [DOI] [PubMed] [Google Scholar]
- Wang F.; Li Z.; Feng X.; Yang D.; Lin M. Advances in PSMA-targeted Therapy for Prostate Cancer. Prostate Cancer and Prostatic Diseases 2022, 25 (1), 11–26. 10.1038/s41391-021-00394-5. [DOI] [PubMed] [Google Scholar]
- Sallam M.; Nguyen N.-T.; Sainsbury F.; Kimizuka N.; Muyldermans S.; Benešová-Schäfer M. PSMA-targeted Radiotheranostics in Modern Nuclear Medicine: Then, Now, and What of the Future?. Theranostics 2024, 14 (8), 3043–3079. 10.7150/thno.92612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fendler W. P.; Eiber M.; Beheshti M.; Bomanji J.; Calais J.; Ceci F.; Cho S. Y.; Fanti S.; Giesel F. L.; Goffin K.; Haberkorn U.; Jacene H.; Koo P. J.; Kopka K.; Krause B. J.; Lindenberg L.; Marcus C.; Mottaghy F. M.; Oprea-Lager D. E.; Osborne J. R.; Piert M.; Rowe S. P.; Schöder H.; Wan S.; Wester H.-J.; Hope T. A.; Herrmann K. PSMA PET/CT: Joint EANM Procedure Guideline/SNMMI Procedure Standard for Prostate Cancer Imaging 2.0. European Journal of Nuclear Medicine and Molecular Imaging 2023, 50 (5), 1466–1486. 10.1007/s00259-022-06089-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fallah J.; Agrawal S.; Gittleman H.; Fiero M. H.; Subramaniam S.; John C.; Chen W.; Ricks T. K.; Niu G.; Fotenos A.; Wang M.; Chiang K.; Pierce W. F.; Suzman D. L.; Tang S.; Pazdur R.; Amiri-Kordestani L.; Ibrahim A.; Kluetz P. G. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin. Cancer Res. 2023, 29 (9), 1651–1657. 10.1158/1078-0432.CCR-22-2875. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kopka K.; Benešová M.; Bařinka C.; Haberkorn U.; Babich J. Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. J. Nucl. Med. 2017, 58 (Supplement 2), 17S–26S. 10.2967/jnumed.116.186775. [DOI] [PubMed] [Google Scholar]
- Kozikowski A. P.; Nan F.; Conti P.; Zhang J.; Ramadan E.; Bzdega T.; Wroblewska B.; Neale J. H.; Pshenichkin S.; Wroblewski J. T. Design of Remarkably Simple, Yet Potent Urea-Based Inhibitors of Glutamate Carboxypeptidase II (NAALADase). J. Med. Chem. 2001, 44 (3), 298–301. 10.1021/jm000406m. [DOI] [PubMed] [Google Scholar]
- Banerjee S. R.; Foss C. A.; Castanares M.; Mease R. C.; Byun Y.; Fox J. J.; Hilton J.; Lupold S. E.; Kozikowski A. P.; Pomper M. G. Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA). J. Med. Chem. 2008, 51 (15), 4504–4517. 10.1021/jm800111u. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hillier S. M.; Maresca K. P.; Lu G.; Merkin R. D.; Marquis J. C.; Zimmerman C. N.; Eckelman W. C.; Joyal J. L.; Babich J. W. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. J. Nucl. Med. 2013, 54 (8), 1369–1376. 10.2967/jnumed.112.116624. [DOI] [PubMed] [Google Scholar]
- Kularatne S. A.; Zhou Z.; Yang J.; Post C. B.; Low P. S. Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents. Mol. Pharmaceutics 2009, 6 (3), 790–800. 10.1021/mp9000712. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Robu S.; Schottelius M.; Eiber M.; Maurer T.; Gschwend J.; Schwaiger M.; Wester H.-J. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. J. Nucl. Med. 2017, 58 (2), 235–242. 10.2967/jnumed.116.178939. [DOI] [PubMed] [Google Scholar]
- Kunert J.-P.; Müller M.; Günther T.; Stopper L.; Urtz-Urban N.; Beck R.; Wester H.-J. Synthesis and Preclinical Evaluation of Novel 99mTc-labeled PSMA Ligands for Radioguided Surgery of Prostate Cancer. EJNMMI Res. 2023, 13 (1), 2. 10.1186/s13550-022-00942-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cardinale J.; Giesel F. L.; Wensky C.; Rathke H. G.; Haberkorn U.; Kratochwil C. PSMA-GCK01 - A Generator-Based 99mTc-/188Re-Theranostic Ligand for the Prostate-Specific Membrane Antigen. J. Nucl. Med. 2023, 64 (7), 1069–1075. 10.2967/jnumed.122.264944. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maurin M.; Wyczółkowska M.; Sawicka A.; Sikora A. E.; Karczmarczyk U.; Janota B.; Radzik M.; Kłudkiewicz D.; Pijarowska-Kruszyna J.; Jaroń A.; Wojdowska W.; Garnuszek P. [99mTc]Tc-PSMA-T4; Novel SPECT Tracer for Metastatic PCa: From Bench to Clinic. Molecules 2022, 27 (21), 7216. 10.3390/molecules27217216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ferro-Flores G.; Luna-Gutiérrez M.; Ocampo-García B.; Santos-Cuevas C.; Azorín-Vega E.; Jiménez-Mancilla N.; Orocio-Rodríguez E.; Davanzo J.; García-Pérez F. O. Clinical Translation of a PSMA Inhibitor for (99m)Tc-based SPECT. Nucl. Med. Biol. 2017, 48, 36–44. 10.1016/j.nucmedbio.2017.01.012. [DOI] [PubMed] [Google Scholar]
- Brunello S.; Salvarese N.; Carpanese D.; Gobbi C.; Melendez-Alafort L.; Bolzati C. A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer. Molecules 2022, 27 (9), 2617. 10.3390/molecules27092617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goffin K. E.; Joniau S.; Tenke P.; Slawin K.; Klein E. A.; Stambler N.; Strack T.; Babich J.; Armor T.; Wong V. Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection. J. Nucl. Med. 2017, 58 (9), 1408–1413. 10.2967/jnumed.116.187807. [DOI] [PubMed] [Google Scholar]
- Ellis W. J.; Donnelly B. J.; Gorin M. A.; Pouliot F.; Nguyen H. G.; Carroll P. R.; Scherr D.; Probst S.; Saperstein L.; Fleshner N.; Maroni P.; Shah K.; Stambler N.; DiPippo V. A.; Strack T.; Mahmood S.; Jensen J.; Wong V.; Allaf M. PD60–11 A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low Grade Prostate Cancer Who Are Candidates for Active Survaillance (PROSPECT-AS). J. Urol. 2019, 201 (Supplement 4), e1100 10.1097/01.JU.0000557222.99762.6b. [DOI] [Google Scholar]
- Boschi A.; Uccelli L.; Martini P. A Picture of Modern Tc-99m Radiopharmaceuticals: Production, Chemistry, and Applications in Molecular Imaging. Applied Sciences 2019, 9 (12), 2526. 10.3390/app9122526. [DOI] [Google Scholar]
- Poschenrieder A.; Taleska J.; Schaetz L. (177)Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?. J. Nucl. Med. 2024, 65 (9), 1340–1342. 10.2967/jnumed.124.267951. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hlatky M. A.; Shilane D.; Hachamovitch R.; DiCarli M. F. Economic Outcomes in the Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles in Coronary Artery Disease Registry: The SPARC Study. Journal of the American College of Cardiology 2014, 63 (10), 1002–1008. 10.1016/j.jacc.2013.11.038. [DOI] [PubMed] [Google Scholar]
- Javan-Noughabi J.; Rezapour A.; Hajahmadi M.; Alipour V. Cost-effectiveness of Single-Photon Emission Computed Tomography for Diagnosis of Coronary Artery Disease: A Systematic Review of the Key Drivers and Quality of Published Literature. Clinical Epidemiology and Global Health 2019, 7 (3), 389–395. 10.1016/j.cegh.2018.07.008. [DOI] [Google Scholar]
- Barinka C.; Byun Y.; Dusich C. L.; Banerjee S. R.; Chen Y.; Castanares M.; Kozikowski A. P.; Mease R. C.; Pomper M. G.; Lubkowski J. Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization. J. Med. Chem. 2008, 51 (24), 7737–7743. 10.1021/jm800765e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maresca K. P.; Hillier S. M.; Femia F. J.; Keith D.; Barone C.; Joyal J. L.; Zimmerman C. N.; Kozikowski A. P.; Barrett J. A.; Eckelman W. C.; Babich J. W. A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer. J. Med. Chem. 2009, 52 (2), 347–357. 10.1021/jm800994j. [DOI] [PubMed] [Google Scholar]
- Benešová M.; Bauder-Wüst U.; Schäfer M.; Klika K. D.; Mier W.; Haberkorn U.; Kopka K.; Eder M. Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J. Med. Chem. 2016, 59 (5), 1761–1775. 10.1021/acs.jmedchem.5b01210. [DOI] [PubMed] [Google Scholar]
- Banerjee S. R.; Pullambhatla M.; Foss C. A.; Falk A.; Byun Y.; Nimmagadda S.; Mease R. C.; Pomper M. G. Effect of Chelators on the Pharmacokinetics of 99mTc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA). J. Med. Chem. 2013, 56 (15), 6108–6121. 10.1021/jm400823w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Oya S.; Plössl K.; Kung M.-P.; Stevenson D. A.; Kung H. F. Small and Neutral Tc(V)O BAT, Bisaminoethanethiol (N2S2) Complexes for Developing New Brain Imaging Agents. Nuclear Medicine and Biology 1998, 25 (2), 135–140. 10.1016/S0969-8051(97)00153-4. [DOI] [PubMed] [Google Scholar]
- Okoye N. C.; Baumeister J. E.; Najafi Khosroshahi F.; Hennkens H. M.; Jurisson S. S. Chelators and Metal Complex Stability for Radiopharmaceutical Applications. Radiochim. Acta 2019, 107 (9–11), 1087–1120. 10.1515/ract-2018-3090. [DOI] [Google Scholar]
- Seifert S.; Gupta A.; Syhre R.; Spies H.; Johannsen B. Ligand-Exchange Reaction of Labile “3 + 1”99mTc(V) Complexes with SH Group-containing Proteins. Applied Radiation and Isotopes 2001, 54 (4), 637–644. 10.1016/S0969-8043(00)00309-2. [DOI] [PubMed] [Google Scholar]
- Pirmettis I.; Pietzsch H.-J.. Technetium-99m Radiopharmaceuticals: Status and Trends; International Atomic Energy Agency: Vienna, 2009; pp 111–136. [Google Scholar]
- Walovitch R. C.; Hill T. C.; Garrity S. T.; Cheesman E. H.; Burgess B. A.; O’Leary D. H.; Watson A. D.; Ganey M. V.; Morgan R. A.; Williams S. J. Characterization of Technetium-99m-L,L-ECD for Brain Perfusion Imaging, Part 1: Pharmacology of Technetium-99m ECD in Nonhuman Primates. J. Nucl. Med. 1989, 30 (11), 1892–1901. [PubMed] [Google Scholar]
- Meegalla S. K.; Plössl K.; Kung M.-P.; Chumpradit S.; Stevenson D. A.; Kushner S. A.; McElgin W. T.; Mozley P. D.; Kung H. F. Synthesis and Characterization of Technetium-99m-Labeled Tropanes as Dopamine Transporter-Imaging Agents. J. Med. Chem. 1997, 40 (1), 9–17. 10.1021/jm960532j. [DOI] [PubMed] [Google Scholar]
- Weineisen M.; Schottelius M.; Simecek J.; Baum R. P.; Yildiz A.; Beykan S.; Kulkarni H. R.; Lassmann M.; Klette I.; Eiber M.; Schwaiger M.; Wester H.-J. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J. Nucl. Med. 2015, 56 (8), 1169–1176. 10.2967/jnumed.115.158550. [DOI] [PubMed] [Google Scholar]
- Oshikiri S.; Uehara T.; Suzuki H.; Koike-Satake M.; Hino A.; Arano Y. Zn Complex of Diaminedithiol Tetradentate Ligand as a Stable Precursor for 99mTc-Labeled Compounds. Molecules 2020, 25 (2), 254. 10.3390/molecules25020254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kung H. F.; Molnar M.; Billings J.; Wicks R.; Blau M. Synthesis and Biodistribution of Neutral Lipid-Soluble Tc-99m Complexes that Cross the Blood-Brain Barrier. J. Nucl. Med. 1984, 25 (3), 326–332. [PubMed] [Google Scholar]
- Alberto R. The “Carbonyl Story” and Beyond; Experiences Lessons and Implications. ChemBioChem. 2020, 21 (19), 2743–2749. 10.1002/cbic.202000387. [DOI] [PubMed] [Google Scholar]
- Kuniyil Kulangara V. R.; Hegde R.. Imaging Tuberculosis with Pyrazinamide Contrast Agents. WO2012022812A1, 2012.
- Dean R. T.; Buttram S.; McBride W.; Lister-James J.; Civitello E. R.. Technetium-99m labeled Peptides for Imaging. US5776428, 1998.
- Corbin J. L.; Work D. E. 1-Alkyl- (or Aryl-) Amino-2-methylpropane-2-thiols. Bi- and Tetradentate Nitrogen-Sulfur Ligands from Schiff’s Base Disulfides. Journal of Organic Chemistry 1976, 41 (3), 489–491. 10.1021/jo00865a016. [DOI] [Google Scholar]
- Merz K. W.; Specker M. Kondensationsversuche mit 2,2,5,5-Tetramethyl-3,4-dithiahexandial-(1,6). Archiv der Pharmazie 1963, 296 (7), 427–438. 10.1002/ardp.19632960704. [DOI] [PubMed] [Google Scholar]
- Zolle I.Technetium-99m Pharmaceuticals: Preparation and Quality Control in Nuclear Medicine; Springer: Berlin, Heidelberg, 2007. [Google Scholar]
- International Atomic Energy Agency Technetium-99m Radiopharmaceuticals: Manufacture of Kits; International Atomic Energy Agency: Vienna, 2008. [Google Scholar]
- Steigman J.; Eckelman W. C.. The Chemistry of Technetium in Medicine; National Academy Press, 1992; pp 111–130. [Google Scholar]
- Troyer J. K.; Beckett M. L.; Wright G. L. Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids. Int. J. Cancer 1995, 62 (5), 552–558. 10.1002/ijc.2910620511. [DOI] [PubMed] [Google Scholar]
- Gorges T. M.; Riethdorf S.; von Ahsen O.; Nastał Y. P.; Röck K.; Boede M.; Peine S.; Kuske A.; Schmid E.; Kneip C.; König F.; Rudolph M.; Pantel K. Heterogeneous PSMA Expression on Circulating Tumor Cells: A Potential Basis for Stratification and Monitoring of PSMA-directed Therapies in Prostate Cancer. Oncotarget 2016, 7 (23), 34930–34941. 10.18632/oncotarget.9004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bhamidipati M.; Lee G.; Kim I.; Fabris L. SERS-Based Quantification of PSMA in Tissue Microarrays Allows Effective Stratification of Patients with Prostate Cancer. ACS Omega 2018, 3 (12), 16784–16794. 10.1021/acsomega.8b01839. [DOI] [Google Scholar]
- Weineisen M.; Simecek J.; Schottelius M.; Schwaiger M.; Wester H.-J. Synthesis and Preclinical Evaluation of DOTAGA-conjugated PSMA Ligands for Functional Imaging and Endoradiotherapy of Prostate Cancer. EJNMMI Res. 2014, 4 (1), 63. 10.1186/s13550-014-0063-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hall S. A.; Hickey A. D.; Hore D. K. Structure of Phenylalanine Adsorbed on Polystyrene from Nonlinear Vibrational Spectroscopy Measurements and Electronic Structure Calculations. J. Phys. Chem. C 2010, 114 (21), 9748–9757. 10.1021/jp910205m. [DOI] [Google Scholar]
- Perkin Elmer Informatics, Inc. ChemDraw, 21.0; Perkin Elmer Informatics, Inc. [Google Scholar]
- Liu T.; Wu L. Y.; Kazak M.; Berkman C. E. Cell-Surface Labeling and Internalization by a Fluorescent Inhibitor of Prostate-Specific Membrane Antigen. Prostate 2008, 68 (9), 955–964. 10.1002/pros.20753. [DOI] [PubMed] [Google Scholar]
- Cardinale J.; Roscher M.; Schäfer M.; Geerlings M.; Benešová M.; Bauder-Wüst U.; Remde Y.; Eder M.; Nováková Z.; Motlová L.; Barinka C.; Giesel F. L.; Kopka K. Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors. J. Med. Chem. 2020, 63 (19), 10897–10907. 10.1021/acs.jmedchem.9b01479. [DOI] [PubMed] [Google Scholar]
- Huang S. S.; Wang X.; Zhang Y.; Doke A.; DiFilippo F. P.; Heston W. D. Improving the Biodistribution of PSMA-targeting Tracers with a Highly Negatively Charged Linker. Prostate 2014, 74 (7), 702–713. 10.1002/pros.22789. [DOI] [PubMed] [Google Scholar]
- Sabet A.; Ahmadzadehfar H.; Muckle M.; Haslerud T.; Wilhelm K.; Biersack H.-J.; Ezziddin S. Significance of Oral Administration of Sodium Perchlorate in Planning Liver-Directed Radioembolization. J. Nucl. Med. 2011, 52 (7), 1063–1067. 10.2967/jnumed.110.083626. [DOI] [PubMed] [Google Scholar]
- Harper P. V.; Lathrop K. A.; Jiminez F.; Fink R.; Gottschalk A. Technetium-99m as a Scanning Agent. Radiology 1965, 85 (1), 101–109. 10.1148/85.1.101. [DOI] [PubMed] [Google Scholar]
- Schmittgen T. D.; Zakrajsek B. A.; Hill R. E.; Liu Q.; Reeves J. J.; Axford P. D.; Singer M. J.; Reed M. W. Expression Pattern of Mouse Homolog of Prostate-Specific Membrane Antigen (FOLH1) in the Transgenic Adenocarcinoma of the Mouse Prostate Model. Prostate 2003, 55 (4), 308–316. 10.1002/pros.10241. [DOI] [PubMed] [Google Scholar]
- Meegalla S. K.; Plössl K.; Kung M.-P.; Stevenson D. A.; Mu; Kushner S.; Liable-Sands L. M.; Rheingold A. L.; Kung H. F. Specificity of Diastereomers of [99mTc]TRODAT-1 as Dopamine Transporter Imaging Agents. J. Med. Chem. 1998, 41 (4), 428–436. 10.1021/jm970742b. [DOI] [PubMed] [Google Scholar]
- Mahmood A.; Halpin W. A.; Baidoo K. E.; Sweigart D. A.; Lever S. Z. Structure of a Neutral N-alkylated Diaminedithiol (dadt) 99TcV Complex: syn[99TcO(NEt-tmdadt)]. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1991, 47 (Pt 2), 254–257. 10.1107/S0108270190008927. [DOI] [PubMed] [Google Scholar]
- Lever S. Z.; Sun S. Y.; Scheffel U. A.; Kaltovich F. A.; Baidoo K. E.; Goldfarb H.; Wagner H. N. Pulmonary Accumulation of Neutral Diamine Dithiol Complexes of Technetium-99m. J. Pharm. Sci. 1994, 83 (6), 802–809. 10.1002/jps.2600830609. [DOI] [PubMed] [Google Scholar]
- Jackson P. F.; Cole D. C.; Slusher B. S.; Stetz S. L.; Ross L. E.; Donzanti B. A.; Trainor D. A. Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated α-Linked Acidic Dipeptidase. J. Med. Chem. 1996, 39 (2), 619–622. 10.1021/jm950801q. [DOI] [PubMed] [Google Scholar]
- Eder M.; Schäfer M.; Bauder-Wüst U.; Hull W.-E.; Wängler C.; Mier W.; Haberkorn U.; Eisenhut M. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjugate Chem. 2012, 23 (4), 688–697. 10.1021/bc200279b. [DOI] [PubMed] [Google Scholar]
- Keenan M. A.; Stabin M. G.; Segars W. P.; Fernald M. J. RADAR Realistic Animal Model Series for Dose Assessment. J. Nucl. Med. 2010, 51 (3), 471–476. 10.2967/jnumed.109.070532. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.










